

FILE 'HOME' ENTERED AT 20:21:07 ON 18 SEP 2002

=> index cheistry polymer bioscience patents pharmacology medicine

'CHEISTRY' IS NOT A VALID FILE NAME

ENTER A FILE NAME OR (IGNORE):chemistry

'BIOSCIENCE' IS NOT A VALID FILE NAME

ENTER A FILE NAME OR (IGNORE):bioscience

FILE 'DRUGMONOS' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS

SINCE FILE TOTAL

ENTRY SESSION

FULL ESTIMATED COST

0.42

0.42

INDEX 'AGRICOLA, ALUMINIUM, ANABSTR, AQUIRE, BABS, BIOCOMMERCE, BIOTECHNO, CABA, CAOLD, CAPLUS, CBNS, CEABA-VTB, CEN, CERAB, CIN, COMPENDEX, CONFSCI, COPPERLIT, CORROSION, DKILIT, ENCOMPLIT, ENCOMPLIT2, FEDRIP, GENBANK, INSPEC, INSPHYS, INVESTEXT, IPA, ...' ENTERED AT 20:22:09 ON 18 SEP 2002

108 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0* with SET DETAIL OFF.

=> s cyclosporin and (synthesis or synthesised)

2 FILE AGRICOLA
3 FILE ANABSTR
48 FILE BABS
554 FILE BIOTECHNO
11 FILE CABA
309 FILE CAPLUS
7 FILE CBNS
2 FILE CEABA-VTB
15 FILE CEN
3 FILE CIN
1 FILE COMPENDEX
3 FILE CONFSCI
11 FILE FEDRIP
1 FILE GENBANK
16 FILE INVESTEXT
9 FILE IPA
44 FILE JICST-EPLUS
5 FILE KOSMET
5 FILE NAPFALEFT

32 FILES SEARCHED...

1 FILE NIOSHTIC
5 FILE NTIS
216 FILE PASCAL
26 FILE PROMT
2 FILE PAPFA
568 FILE SCISEARCH
40 FILE IFIPAT
2644 FILE USPATFULL
22 FILE USPAT2
55 FILE WFIDS
55 FILE WPINDEX
57 FILE ADISALEFTS
35 FILE ADISINSIGHT
13 FILE ADISNEWS
14 FILE BIOBUSINESS
744 FILE BIOSIS
14 FILE BIOTECHABS
14 FILE BIOTECHDS

61 FILES SEARCHED...

363 FILE CANCEFLIT
3 FILE DDFB
277 FILE DDFU

3 FILE DRUGB
 475 FILE DRUGU
 1 FILE DRUGUPDATES
 5 FILE EMBAL
 1719 FILE EMBASE
 273 FILE EMBIOBASE
 4 FILE HEALSAFE
 265 FILE LIFESCI
 814 FILE MEDLINE
 1 FILE OCEAN
 13 FILE PHAR
 1 FILE PHIC
 3 FILE PHIN
 1 FILE SYNTHLINE
 713 FILE TOXCENTER
 3 FILE VETU
 93 FILES SEARCHED...
 4 FILE DPCI
 518 FILE EUROPATFULL
 11 FILE INFADOC
 6 FILE PATOSEP
 6 FILE PATOSWO
 995 FILE PCTFULL
 15 FILE NLDB

63 FILES HAVE ONE OR MORE ANSWERS, 108 FILES SEARCHED IN STNINDEX

L1 QUE CYCLOSPORIN AND (SYNTHESIS OR SYNTHESISED)

=> file hits

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	3.18	3.60

FILE 'USPATFULL' ENTERED AT 20:25:42 ON 18 SEP 2002
 CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 20:25:42 ON 18 SEP 2002
 COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'PCTFULL' ENTERED AT 20:25:42 ON 18 SEP 2002
 COPYRIGHT (C) 2002 Univentio

FILE 'CAPLUS' ENTERED AT 20:25:42 ON 18 SEP 2002
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 20:25:42 ON 18 SEP 2002

FILE 'BIOSIS' ENTERED AT 20:25:42 ON 18 SEP 2002
 COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'TOXCENTER' ENTERED AT 20:25:42 ON 18 SEP 2002
 COPYRIGHT (C) 2002 ACS

FILE 'SCISEARCH' ENTERED AT 20:25:42 ON 18 SEP 2002
 COPYRIGHT (C) 2002 Institute for Scientific Information (ISI) (R)

FILE 'BIOTECHNO' ENTERED AT 20:25:42 ON 18 SEP 2002
 COPYRIGHT (C) 2002 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'EUROPATFULL' ENTERED AT 20:25:42 ON 18 SEP 2002
 COPYRIGHT (C) 2002 WILA Verlag Muenchen (WILA)

FILE 'DRUGU' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'CANCERLIT' ENTERED AT 20:25:42 ON 18 SEP 2002

FILE 'DIFU' ACCESS NOT AUTHORIZED

FILE 'ESBIOBASE' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'LIFESCI' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 20:25:42 ON 18 SEP 2002
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2002 INIST-CNRS. All rights reserved.

FILE 'ADISALERTS' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 Adis International Ltd. (ADIS)

FILE 'WPIDS' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

FILE 'BABS' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften
licensed to Beilstein Chemedaten & Software GmbH and MDL Information Systems GmbH

FILE 'JICST-EPLUS' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 Japan Science and Technology Corporation (JST)

FILE 'IFIPAT' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 IFI CLAIMS(R) Patent Services (IFI)

FILE 'ADISINSIGHT' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 Adis International Ltd. (ADIS)

FILE 'PROMT' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 Gale Group. All rights reserved.

FILE 'USPAT2' ENTERED AT 20:25:42 ON 18 SEP 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CABA' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 CAB INTERNATIONAL (CABI)

FILE 'INVESTEXT' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 Thomson Financial Services, Inc. (TFS)

FILE 'CEN' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 American Chemical Society (ACS)

FILE 'NLDB' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 Gale Group. All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 Biological Abstracts, Inc. (BIOSIS)

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 20:25:42 ON 18 SEP 2002

COPYRIGHT (C) 2002 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'ADISNEWS' ENTERED AT 20:25:42 ON 18 SEP 2002

COPYRIGHT (C) 2002 Adis International Ltd. (ADIS)

FILE 'PHAR' ENTERED AT 20:25:42 ON 18 SEP 2002

COPYRIGHT (C) 2002 PCB Publications Ltd. (PCB)

FILE 'FEDRIF' ENTERED AT 20:25:42 ON 18 SEP 2002

FILE 'INPADOC' ENTERED AT 20:25:42 ON 18 SEP 2002

COPYRIGHT (C) 2002 European Patent Office, Vienna (EPO)

FILE 'AGRICOLA' ENTERED AT 20:25:42 ON 18 SEP 2002

FILE 'IPA' ENTERED AT 20:25:42 ON 18 SEP 2002

COPYRIGHT (C) 2002 American Society of Hospital Pharmacists (ASHP)

FILE 'CENE' ENTERED AT 20:25:42 ON 18 SEP 2002

COPYRIGHT (C) 2002 ELSEVIER ENGINEERING INFORMATION, INC.

FILE 'PATOSEP' ENTERED AT 20:25:42 ON 18 SEP 2002

COPYRIGHT (C) 2002 WILA Verlag Muenchen (WILA)

FILE 'PATOSWO' ENTERED AT 20:25:42 ON 18 SEP 2002

COPYRIGHT (C) 2002 WILA Verlag Muenchen (WILA)

FILE 'KOSMET' ENTERED AT 20:25:42 ON 18 SEP 2002

COPYRIGHT (C) 2002 International Federation of the Societies of Cosmetics Chemists

FILE 'NAPRALERT' ENTERED AT 20:25:42 ON 18 SEP 2002

COPYRIGHT (C) 2002 Board of Trustees of the University of Illinois,
University of Illinois at Chicago.

FILE 'NTIS' ENTERED AT 20:25:42 ON 18 SEP 2002

Compiled and distributed by the NTIS, U.S. Department of Commerce.

It contains copyrighted material.

All rights reserved. (2002)

FILE 'EMBAL' ENTERED AT 20:25:42 ON 18 SEP 2002

COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'HEALSAFE' ENTERED AT 20:25:42 ON 18 SEP 2002

COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'DPCI' ENTERED AT 20:25:42 ON 18 SEP 2002

COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'ANABSTR' ENTERED AT 20:25:42 ON 18 SEP 2002

COPYRIGHT (C) 2002 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'CIN' ENTERED AT 20:25:42 ON 18 SEP 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 20:25:42 ON 18 SEP 2002

COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'DDFB' ACCESS NOT AUTHORIZED

FILE 'DRUGB' ENTERED AT 20:25:42 ON 18 SEP 2002

COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'PHIN' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 PJB Publications Ltd. (PJB)

FILE 'VETU' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 THOMSON HERWENT

FILE 'CEABA-VTB' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 DEHEMA BV

FILE 'RAPRA' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 RAPRA Technology Ltd.

FILE 'COMPENDEX' ENTERED AT 20:25:42 ON 18 SEP 2002
Compendex Compilation and Indexing (C) 2002
Elsevier Engineering Information Inc (EEI). All rights reserved.
Compendex (R) is a registered Trademark of Elsevier Engineering Information Inc.

FILE 'GENBANK' ENTERED AT 20:25:42 ON 18 SEP 2002

FILE 'NIOSH TIC' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'DRUGUPDATES' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 IMSWORLD Publications Ltd

FILE 'OCEAN' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'PHIC' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 PJB Publications Ltd. (PJB)

FILE 'SYNTHLINE' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 Prous Science

=> s 11 and alkyl

L2	1541	FILE USPATEFULL
L3	6	FILE EMBASE
L4	610	FILE PCTFULL
L5	17	FILE CAPLUS
L6	1	FILE MEDLINE
L7	4	FILE BIOSIS
L8	4	FILE TOXCENTER
L9	4	FILE SCISEARCH
L10	1	FILE BIOTECHNO
L11	283	FILE EUROPEATFULL
L12	2	FILE DRUGU
L13	1	FILE CANCERLIT
L14	0	FILE EMBIOBASE
L15	0	FILE LIFESCI
L16	2	FILE PASCAL
L17	0	FILE ADISALERTS
L18	23	FILE WPIDS
L19	2	FILE BAES
L20	0	FILE JICST-EPLUS
L21	16	FILE IFIPAT
L22	0	FILE ADISINSIGHT
L23	1	FILE PPOMT
L24	14	FILE USPATE2
L25	0	FILE CAEA
L26	1	FILE INVESTEXT
L27	1	FILE CEN
L28	0	FILE NLMB
L29	0	FILE BIOBUSINESS
L30	0	FILE BIOTECHDS

L31	0	FILE ADISNEWS
L32	0	FILE PHAR
L33	0	FILE FEDRIP
L34	0	FILE INFADOC
L35	0	FILE AGRICOLA
L36	0	FILE IPA
L37	0	FILE CENB
L38	0	FILE PATOSEP
L39	0	FILE PATOSWO
L40	0	FILE KOSMET
L41	0	FILE NAFFALERT
L42	0	FILE NTIS
L43	0	FILE EMBAL
L44	0	FILE HEALSAFE
L45	0	FILE DPCI
L46	0	FILE ANABSTR
L47	0	FILE CIN
L48	0	FILE CONFSCI
L49	0	FILE DRUGB
L50	0	FILE PHIN
L51	0	FILE VETU
L52	0	FILE CEABA-VTB
L53	0	FILE RAFPRA
L54	0	FILE COMPENDEX
L55	0	FILE GENBANK
L56	0	FILE NIOSHTIC
L57	0	FILE DRUGUPDATES
L58	0	FILE OCEAN
L59	0	FILE PHIC
L60	0	FILE SYNTHLINE

TOTAL FOR ALL FILES

L61 2534 L1 AND ALKYL

=> s 161 and (pharmaceutical (w) composition)

L62	1223	FILE USPATFULL
L63	0	FILE EMBASE
L64	524	FILE PCTFULL
L65	0	FILE CAPLUS
L66	0	FILE MEDLINE
L67	0	FILE BIOSIS
L68	0	FILE TOXCENTER
L69	0	FILE SCISEARCH
L70	0	FILE BIOTECHNO
L71	209	FILE EUROPATFULL
L72	0	FILE DRUGU
L73	0	FILE CANCERLIT
L74	0	FILE ESBIOBASE
L75	0	FILE LIFESCI
L76	0	FILE PASCAL
L77	0	FILE ADISALERTS
L78	4	FILE WPIDS
L79	0	FILE EABS
L80	0	FILE JICST-EPLUS
L81	10	FILE IFIPAT
L82	0	FILE ADISINSIGHT
L83	0	FILE PROMT
L84	12	FILE USPAT2
L85	0	FILE CABA
L86	0	FILE INVESTEXT
L87	0	FILE CEN
L88	0	FILE NLLS
L89	0	FILE BIOBUSINESS
L90	0	FILE BIOTECHDS
L91	0	FILE ADISNEWS

L92	0	FILE PHAR
L93	0	FILE FEDRIP
L94	0	FILE INPADOC
L95	0	FILE AGRICOLA
L96	0	FILE IPA
L97	0	FILE CBNE
L98	0	FILE PATOSEP
L99	0	FILE PATOSWG
L100	0	FILE KOSMET
L101	0	FILE NAPRALERT
L102	0	FILE NTIS
L103	0	FILE EMBAL
L104	0	FILE HEALSAFE
L105	0	FILE DFCI
L106	0	FILE ANABSTR
L107	0	FILE CIN
L108	0	FILE CONFSCI
L109	0	FILE DRUGB
L110	0	FILE PHIN
L111	0	FILE VETU
L112	0	FILE CEABA-VTB
L113	0	FILE RAFPRA
L114	0	FILE COMPENDEX
L115	0	FILE GENBANK
L116	0	FILE NIOSHTIC
L117	0	FILE DRUGUPDATES
L118	0	FILE OCEAN
L119	0	FILE PHIC
L120	0	FILE SYNTHLINE

TOTAL FOR ALL FILES

L121 1982 L61 AND (PHARMACEUTICAL (W) COMPOSITION)

=> s 1121 and MeBmt

L122	30	FILE USPATFULL
L123	0	FILE EMBASE
L124	1	FILE PCTFULL
L125	0	FILE CAPLUS
L126	0	FILE MEDLINE
L127	0	FILE BIOSIS
L128	0	FILE TOXCENTER
L129	0	FILE SCISEARCH
L130	0	FILE BIOTECHNO
L131	7	FILE EUROPATFULL
L132	0	FILE DRUGU
L133	0	FILE CANCERLIT
L134	0	FILE ESBIORASE
L135	0	FILE LIFESCI
L136	0	FILE PASCAL
L137	0	FILE ADISALERTS
L138	0	FILE WPIDS
L139	0	FILE EABS
L140	0	FILE JICST-EPLUS
L141	0	FILE IFIPAT
L142	0	FILE ADISINSIGHT
L143	0	FILE PROMT
L144	0	FILE USPATE
L145	0	FILE CABA
L146	0	FILE INVESTEXT
L147	0	FILE CEN
L148	0	FILE NLDB
L149	0	FILE BIOBUSINESS
L150	0	FILE BIOTECHIS
L151	0	FILE ADISNEWS
L152	0	FILE PHAR

L153 0 FILE FEDRIP
 L154 0 FILE INPADOC
 L155 0 FILE AGRICOLA
 L156 0 FILE IPA
 L157 0 FILE CBNB
 L158 0 FILE PATOSEP
 L159 0 FILE PATOSWO
 L160 0 FILE KOSMET
 L161 0 FILE NAPFALERT
 L162 0 FILE NTIS
 L163 0 FILE EMBAL
 L164 0 FILE HEALSAFE
 L165 0 FILE DECI
 L166 0 FILE ANABSTR
 L167 0 FILE CIN
 L168 0 FILE CONFSCI
 L169 0 FILE DRUGB
 L170 0 FILE PHIN
 L171 0 FILE VETU
 L172 0 FILE CEABA-VTB
 L173 0 FILE RAPRA
 L174 0 FILE COMPENDEX
 L175 0 FILE GENBANK
 L176 0 FILE NIOSHTIC
 L177 0 FILE DRUGUPDATES
 L178 0 FILE OCEAN
 L179 0 FILE PHIC
 L180 0 FILE SYNTHLINE

TOTAL FOR ALL FILES

L181 38 L121 AND MEBMT

=> d 1181 1-38 ibib abs

L181 ANSWER 1 OF 38 USPATEFULL

ACCESSION NUMBER: 2002:224588 USPATEFULL

TITLE: Methods of using inhibitors of cyclophilin rotamase activity to affect neurological activity

INVENTOR(S): Steiner, Joseph P., Finksburg, MD, United States
 Hamilton, Gregory S., Catonsville, MD, United States
 Snyder, Solomon H., Baltimore, MD, United States

PATENT ASSIGNEE(S): Guilford Pharmaceuticals Inc., Baltimore, MD, United States (U.S. corporation)
 Johns Hopkins University School of Medicine, Baltimore, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6444643	B1	20020903
APPLICATION INFO.:	US 1999-321762		19990528 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-560635, filed on 20 Nov 1995, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Kunz, Gary L.		
ASSISTANT EXAMINER:	Gucker, Stephen		
LEGAL REPRESENTATIVE:	Howrey Simon Arnold & White, LLP		
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)		
LINE COUNT:	923		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to the method of using neurotrophic cyclophilin inhibitor compounds having an affinity for cyclophilin-type immunophilins as inhibitors of the enzyme activity associated with

immunophilin proteins, and particularly inhibitors of peptidyl-prolyl isomerase or rotamase enzyme activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L131 ANSWER 2 OF 38 USPATFULL

ACCESSION NUMBER: 2001:8197 USPATFULL
TITLE: Synthetic transcriptional modulators and uses thereof
INVENTOR(S): Verdine, Gregory L., Lexington, MA, UNITED STATES
Nyangquile, Origene, Gaithersburg, MD, UNITED STATES
PATENT ASSIGNEE(S): President and Fellows of Harvard College (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002004195	A1	20020110
APPLICATION INFO.:	US 2000-751309	A1	20001229 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-208057, filed on 9 Dec 1998, GRANTED, Pat. No. US 6183965 Continuation-in-part of Ser. No. US 1997-987912, filed on 9 Dec 1997, GRANTED, Pat. No. US 6153383		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	FOLEY, HOAG & ELIOT, LLP, PATENT GROUP, ONE POST OFFICE SQUARE, BOSTON, MA, 02109		
NUMBER OF CLAIMS:	33		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	6 Drawing Page(s)		
LINE COUNT:	3196		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel synthetic transcriptional modulators having at least one selected ligand linked to at least one transcriptional modulating portion are described. The transcriptional modulators of the present invention can include a ligand linked to a chemical moiety. These transcriptional modulators can be used to selectively control gene expression and to identify components of the transcriptional machinery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 3 OF 38 USPATFULL

ACCESSION NUMBER: 2001:202601 USPATFULL
TITLE: Regulated apoptosis
INVENTOR(S): Crabtree, Gerald, Woodside, CA, United States
Schreiber, Stuart, Boston, MA, United States
Spencer, David, Houston, TX, United States
Wandless, Thomas, Palo Alto, CA, United States
Belshaw, Peter, Somerville, MA, United States
Ho, Steffan N, San Diego, CA, United States
PATENT ASSIGNEE(S): Board of Trustees of Leland Stanford Junior University, Stanford, CA, United States (U.S. corporation)
President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6316418	B1	20011113
APPLICATION INFO.:	US 1999-302629		19990430 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-87811, filed on 29 May 1993, now patented, Pat. No. US 6054436 Continuation of Ser. No. US 1994-292597, filed on 18 Aug 1994, now patented, Pat. No. US 5834266 Continuation-in-part of Ser. No. US 1994-179143, filed on 7 Jan 1994, now abandoned Continuation-in-part of Ser. No. US 1993-93499, filed on 16 Jul 1993, now abandoned, said Ser. No. US 179143 And Ser. No. US 302629		

Continuation-in-part of Ser. No. US 1994-196043, filed on 11 Feb 1994, now abandoned Continuation-in-part of Ser. No. US 1994-179748, filed on 7 Jan 1994, now abandoned Continuation-in-part of Ser. No. US 1993-92977, filed on 16 Jul 1993, now abandoned Continuation-in-part of Ser. No. US 1993-17931, filed on 12 Feb 1993, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Schwartzman, Robert A.
LEGAL REPRESENTATIVE: Vincent, Matthew P. Ropes & Gray
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 35 Drawing Figure(s); 34 Drawing Page(s)
LINE COUNT: 4291

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins and disclose methods and materials for using that procedure to regulatably initiate cell-specific apoptosis (programmed cell death) in genetically engineered cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 4 OF 38 USPATEFULL

ACCESSION NUMBER: 2001:202588 USPATEFULL
TITLE: **Cyclosporin** a conjugates and uses therefor
INVENTOR(S): Rich, Daniel H., Madison, WI, United States
Solomon, Michael E., Arlington, MA, United States
PATENT ASSIGNEE(S): Wisconsin Alumni Research Foundation, Madison, WI,
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6316405	B1	20011113
APPLICATION INFO.:	US 1999-242724		19990222 (9)
	WO 1998-US17544		19980825
			19990222 PCT 371 date
			19990222 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-57751P	19970826 (50)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Carlson, Karen Cochrane	
ASSISTANT EXAMINER:	Tu, Stephen	
LEGAL REPRESENTATIVE:	Leone, Esq., Joseph T. Dewitt Foss & Stevens S.C.	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2215	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are conjugates of A.beta.-binding peptides and CsA analogs and conjugates of A.beta.-binding peptides and FK506 Binding Peptide inhibitors. These conjugates chemically induce dimerization of either cyclophilin or FK506 Binding Peptide with A.beta. peptide, a major component of amyloid plaques found in neurological disorders such as Alzheimer's disease, multiple sclerosis, and amyotrophic lateral sclerosis. The conjugates are useful in the treatment of neurological diseases involving the formation of amyloid plaques because they inhibit and/or prevent the aggregation and deposition of A.beta. peptide into plaques.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 5 OF 38 USPATEFULL

ACCESSION NUMBER: 2001:125730 USPATEFULL
TITLE: Non-Immunosuppressive **cyclosporins** and their
use in the prevention and treatment of HIV infection
INVENTOR(S): Rich, Daniel H., Madison, WI, United States
Solomon, Michael E., Arlington, MA, United States
PATENT ASSIGNEE(S): Wisconsin Alumni Research Foundation, Madison, WI,
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6,170,957	B1	20010807
	WO 9910373		19990304
APPLICATION INFO.:	US 1999-242723		19990222 (9)
	WO 1998-US17542		19980325
			19990222 PCT 371 date
			19990222 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-57751P	19970326 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Park, Hankyel T.	
LEGAL REPRESENTATIVE:	Leone, Esq., Joseph T. DeWitt Ross & Stevens S.C.	
NUMBER OF CLAIMS:	31	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 4 Drawing Page(s)	
LINE COUNT:	2601	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are **cyclosporin** analogs having amino acid residue substitutions at positions 1, 3, or 7 of the **cyclosporin** peptide backbone. Also disclosed are conjugates of these **cyclosporin** analogs in which an HIV protease inhibitor moiety is conjugated to the position-7 amino acid residue of the **cyclosporin**. These compounds simultaneously bind to and inhibit cyclophilin and HIV protease. The compounds have good bioavailability and potent HIV inhibitory activity. They are useful in the treatment and prevention of HIV-mediated disorders, including AIDS.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 6 OF 38 USPATEFULL

ACCESSION NUMBER: 2001:102610 USPATEFULL
TITLE: **Cyclosporin** fermentation process
INVENTOR(S): Ko, Soo Young, London, United Kingdom
Kobel, Hans, Basel, Switzerland
Besemer-Rosenwirth, Brigitte, Modling, Austria
Seebach, Dieter, Zurich, Switzerland
Traker, Rene P., Basel, Switzerland
Wenger, Roland, Riehen, Switzerland
Bollinger, Pietro, Bottmingen, Switzerland
PATENT ASSIGNEE(S): Novartis AG, Basel, Switzerland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6,255,100	B1	20010703
APPLICATION INFO.:	US 1999-330282		19990909 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-84709, filed on 26 May 1998, now patented, Pat. No. US 5,981,479 Division of Ser. No. US 1995-427312, filed on 24 Apr 1995, now patented, Pat. No. US 5,767,069 Continuation of Ser. No. US 1994-232795, filed on 25 Apr 1994, now abandoned Continuation of Ser. No. US 1993-57067, filed on 3 May 1993, now abandoned Continuation of Ser. No. US		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1990-23859	19901102
	GB 1990-23970	19901105
	GB 1990-23971	19901105
	GB 1990-23972	19901105
	GB 1991-16836	19910805

DOCUMENT TYPE: Utility
 FILE SEGMENT: GRANTED
 PRIMARY EXAMINER: Wessendorf, T. D.
 LEGAL REPRESENTATIVE: Lopez, Gabriel
 NUMBER OF CLAIMS: 3
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
 LINE COUNT: 309

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB It has been found that nonimmunosuppressive, cyclophilin-binding **cyclosporins** are useful in the treatment and prevention of AIDS and AIDS-related disorders. Such **cyclosporins** include novel Cyclosporin derivatives modified at the 4- and/or 5-positions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

LIB1 ANSWER 7 OF 38 USPATFULL

ACCESSION NUMBER: 2001:18213 USPATFULL
 TITLE: Synthetic transcriptional modulators and uses thereof
 INVENTOR(S): Verdine, Gregory L., Lexington, MA, United States
 Nyanquile, Origene, Gaithersburg, MD, United States
 PATENT ASSIGNEE(S): President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6183965	B1	20010206
APPLICATION INFO.:	US 1998-208057		19981209 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-987912, filed on 9 Dec 1997		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Schwartzman, Robert A.		
LEGAL REPRESENTATIVE:	Foley, Hoag & Eliot, LLP, Clauss, Isabelle M., Vincent, Matthew P.		
NUMBER OF CLAIMS:	35		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	11 Drawing Figure(s); 7 Drawing Page(s)		
LINE COUNT:	3213		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel synthetic transcriptional modulators having at least one selected ligand linked to at least one transcriptional modulating portion are described. The transcriptional modulators of the present invention can include a ligand linked to a chemical moiety. These transcriptional modulators can be used to selectively control gene expression and to identify components of the transcriptional machinery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

LIB1 ANSWER 9 OF 38 USPATFULL

ACCESSION NUMBER: 2000:174415 USPATFULL
 TITLE: Regulated transcription of targeted genes and other biological events
 INVENTOR(S): Craktree, Gerald R., Woodside, CA, United States
 Schreiber, Stuart L., Cambridge, MA, United States
 Spencer, David M., Los Altos, CA, United States

PATENT ASSIGNEE(S):

Wandless, Thomas J., Cambridge, MA, United States
 Belshaw, Peter, Cambridge, MA, United States
 Board of Trustees of Leland Stanford Jr. University,
 Stanford, CA, United States (U.S. corporation)
 President and Fellows of Harvard College, Cambridge,
 MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6166787		20001226
APPLICATION INFO.:	US 1998-87647		19980529 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-473386, filed on 7 Jun 1995, now patented, Pat. No. US 5930462 And a continuation-in-part of Ser. No. US 1994-292597, filed on 18 Aug 1994, now patented, Pat. No. US 5834266 which is a continuation-in-part of Ser. No. US 1994-179143, filed on 7 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-93499, filed on 16 Jul 1993, now abandoned, said Ser. No. US 478386 which is a division of Ser. No. US 1995-339653, filed on 14 Feb 1995, now patented, Pat. No. US 5969337 which is a continuation-in-part of Ser. No. US 1994-196043, filed on 11 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-179748, filed on 7 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-42977, filed on 16 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-17931, filed on 12 Feb 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Elliott, George C.		
ASSISTANT EXAMINER:	Schwartzman, Robert		
LEGAL REPRESENTATIVE:	Bernstein, David L., Hausdorff, Sharon F., Clauss, Isabelle M.		
NUMBER OF CLAIMS:	129		
EXEMPLARY CLAIM:	62		
NUMBER OF DRAWINGS:	36 Drawing Figure(s); 36 Drawing Page(s)		
LINE COUNT:	5058		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Dimerization and oligomerization of proteins are general biological control mechanisms that contribute to the activation of cell membrane receptors, transcription factors, vesicle fusion proteins, and other classes of intra- and extracellular proteins. We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins. In principle, any two target proteins can be induced to associate by treating the cells or organisms that harbor them with cell-permeable, synthetic ligands. To illustrate the practice of this invention, we have induced: (1) the intracellular aggregation of the cytoplasmic tail of the ζ chain of the T cell receptor (TCR)-CD3 complex thereby leading to signaling and transcription of a reporter gene, (2) the homodimerization of the cytoplasmic tail of the Fas receptor thereby leading to cell-specific apoptosis (programmed cell death) and (3) the heterodimerization of a DNA-binding domain (Gal4) and a transcription-activation domain (VP16) thereby leading to direct transcription of a reporter gene. Regulated intracellular protein association with our cell permeable, synthetic ligands offers new capabilities in biological research and medicine, in particular, in gene therapy. Using gene transfer techniques to introduce our artificial receptors, one can turn on or off the signaling pathways that lead to the overexpression of therapeutic proteins by administering orally active "dimerizers" or "de-dimerizers", respectively. Since cells from different recipients can be configured to have the pathway overexpress different therapeutic proteins for use in a variety of disorders, the dimerizers have the potential to serve as "universal

drugs". They can also be viewed as cell permeable, organic replacements for therapeutic antisense agents or for proteins that would otherwise require intravenous injection or intracellular expression (e.g., the LDL receptor or the CFTR protein).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 9 OF 38 USPATEFULL

ACCESSION NUMBER: 2000:160780 USPATEFULL
TITLE: Synthetic transcriptional modulators and uses thereof
INVENTOR(S): Verdine, Gregory L., 91 Outlook Dr., Lexington, MA,
United States 02173
Nyanguile, Origene, 2517 Baltimore Rd. #4, Rockville,
MD, United States 20853

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6153383		20001128
APPLICATION INFO.:	US 1997-987912		19971209 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Schwartzman, Robert A.		
LEGAL REPRESENTATIVE:	Foley, Hoag & Eliot LLP, Vincent, Matthew P., Clauss, Isabelle M.		
NUMBER OF CLAIMS:	35		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	7 Drawing Figure(s); 4 Drawing Page(s)		
LINE COUNT:	2397		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel synthetic transcriptional modulators having at least one selected ligand linked to at least one transcriptional modulating portion are described. The transcriptional modulators of the present invention can include a ligand linked to a chemical moiety. These transcriptional modulators can be used to selectively control gene expression and to identify components of the transcriptional machinery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 10 OF 38 USPATEFULL

ACCESSION NUMBER: 2000:50686 USPATEFULL
TITLE: Regulated apoptosis
INVENTOR(S): Crabtree, Gerald R., Woodside, CA, United States
Schreiber, Stuart L., Cambridge, MA, United States
Spencer, David M., Los Altos, CA, United States
Wandless, Thomas J., Cambridge, MA, United States
Belshaw, Peter, Cambridge, MA, United States
PATENT ASSIGNEE(S): Board of Trustees of Leland S. Stanford Jr. Univ.,
Stanford, CA, United States (U.S. corporation)
President & Fellows of Harvard College, Cambridge, MA,
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6054436		20000425
APPLICATION INFO.:	US 1998-87311		19980529 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-292597, filed on 18 Aug 1994, now patented, Pat. No. US 5834266 which is a continuation-in-part of Ser. No. US 1994-172143, filed on 7 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-93499, filed on 16 Jul 1993, now abandoned And a continuation-in-part of Ser. No. US 1994-196043, filed on 14 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-179748, filed on 7 Jan 1994, now abandoned which is a		

continuation-in-part of Ser. No. US 1993-91977, filed
on 16 Jul 1993, now abandoned which is a
continuation-in-part of Ser. No. US 1993-17931, filed
on 12 Feb 1993, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Elliott, George C.
ASSISTANT EXAMINER: Schwartzman, Robert
LEGAL REPRESENTATIVE: Bernstein, David L., Hausdorff, Sharon F., Clauss,
Isabelle M.
NUMBER OF CLAIMS: 64
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 35 Drawing Figure(s); 34 Drawing Page(s)
LINE COUNT: 5061

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB We have developed a general procedure for the regulated (inducible)
dimerization or oligomerization of intracellular proteins and disclose
methods and materials for using that procedure to regulatably initiate
cell-specific apoptosis (programmed cell death) in genetically
engineered cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L191 ANSWER 11 OF 38 USPATEFULL

ACCESSION NUMBER: 2000:40892 USPATEFULL
TITLE: Regulated transcription of targeted genes and other
biological events
INVENTOR(S): Crabtree, Gerald R., Woodside, CA, United States
Schreiber, Stuart L., Cambridge, MA, United States
Spencer, David M., Los Altos, CA, United States
Wandless, Thomas J., Cambridge, MA, United States
Belshaw, Peter, Cambridge, MA, United States
Ho, Steffan N., San Diego, CA, United States
PATENT ASSIGNEE(S): Board of Trustees of Leland Stanford Jr. University,
Stanford, CA, United States (U.S. corporation)
President and Fellows of Harvard College, Cambridge,
MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6046047		20000404
APPLICATION INFO.:	US 1998-157230		19980916 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-388653, filed on 14 Feb 1995, now patented, Pat. No. US 5869337 And a continuation-in-part of Ser. No. US 1994-292597, filed on 18 Aug 1994, now patented, Pat. No. US 5834266 which is a continuation-in-part of Ser. No. US 1994-179143, filed on 7 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-93499, filed on 16 Jul 1993, now abandoned, said Ser. No. US 388653 which is a continuation-in-part of Ser. No. US 1994-196043, filed on 14 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-179748, filed on 7 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-92977, filed on 16 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-17931, filed on 12 Feb 1993, now abandoned		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Degen, Nancy
ASSISTANT EXAMINER: Schwartzman, Robert
LEGAL REPRESENTATIVE: Bernstein, David L., Vincent, Matthew P., Clauss,
Isabelle M.
NUMBER OF CLAIMS: 127

EXEMPLARY CLAIM: 65
NUMBER OF DRAWINGS: 37 Drawing Figure(s); 36 Drawing Page(s)
LINE COUNT: 4582
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Dimerization and oligomerization of proteins are general biological control mechanisms that contribute to the activation of cell membrane receptors, transcription factors, vesicle fusion proteins, and other classes of intra- and extracellular proteins. We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins. In principle, any two target proteins can be induced to associate by treating the cells or organisms that harbor them with cell permeable, synthetic ligands. To illustrate the practice of this invention, we have induced: (1) the intracellular aggregation of the cytoplasmic tail of the zeta chain of the T cell receptor (TCR)-CD3 complex thereby leading to signaling and transcription of a reporter gene, (2) the homodimerization of the cytoplasmic tail of the Fas receptor thereby leading to cell-specific apoptosis (programmed cell death) and (3) the heterodimerization of a DNA-binding domain (Gal4) and a transcription-activation domain (VP16) thereby leading to direct transcription of a reporter gene. Regulated intracellular protein association with our cell permeable, synthetic ligands offers new capabilities in biological research and medicine, in particular, in gene therapy. Using gene transfer techniques to introduce our artificial receptors, one can turn on or off the signaling pathways that lead to the overexpression of therapeutic proteins by administering orally active "dimerizers" or "de-dimerizers", respectively. Since cells from different recipients can be configured to have the pathway overexpress different therapeutic proteins for use in a variety of disorders, the dimerizers have the potential to serve as "universal drugs". They can also be viewed as cell permeable, organic replacements for therapeutic antisense agents or for proteins that would otherwise require intravenous injection or intracellular expression (e.g., the LDL receptor or the CFTR protein).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 12 OF 38 USPATEFULL

ACCESSION NUMBER: 2000:37639 USPATEFULL

TITLE: Regulated transcription of targeted genes and other biological events

INVENTOR(S): Crabtree, Gerald R., Woodside, CA, United States
Schreiber, Stuart L., Cambridge, MA, United States
Spencer, David M., Los Altos, CA, United States
Wandless, Thomas J., Cambridge, MA, United States
Ho, Steffan N., San Diego, CA, United States
Belshaw, Peter, Cambridge, MA, United States
PATENT ASSIGNEE(S): Board of Trustees of Leland Stanford Jr. Univ.,
Stanford, CA, United States (U.S. corporation)
President & Fellows of Harvard College, Cambridge, MA,
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6043082		20000328
APPLICATION INFO.:	US 1998-157753		19980916 (3)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-388653, filed on 14 Feb 1995, now patented, Pat. No. US 5869337 which is a continuation-in-part of Ser. No. US 1994-196043, filed on 14 Feb 1994 which is a continuation-in-part of Ser. No. US 1994-179748, filed on 7 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-92977, filed on 16 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-17931, filed on 12 Feb 1993, now abandoned And a continuation of Ser. No. US 1994-292597, filed on 18 Aug 1994, now		

patented, Pat. No. US 5334266 which is a continuation-in-part of Ser. No. US 1994-179143, filed on 7 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-93499, filed on 16 Jul 1993, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Elliott, George C.
ASSISTANT EXAMINER: Schwartzman, Robert
LEGAL REPRESENTATIVE: Bernstein, David L., Vincent, Matthew P., Clauss, Isabelle M.

NUMBER OF CLAIMS: 71
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 37 Drawing Figure(s); 36 Drawing Page(s)
LINE COUNT: 4828

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Dimerization and oligomerization of proteins are general biological control mechanisms that contribute to the activation of cell membrane receptors, transcription factors, vesicle fusion proteins, and other classes of intra- and extracellular proteins. We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins. In principle, any two target proteins can be induced to associate by treating the cells or organisms that harbor them with cell permeable, synthetic ligands. To illustrate the practice of this invention, we have induced: (1) the intracellular aggregation of the cytoplasmic tail of the ζ chain of the T cell receptor (TCR)CD3 complex thereby leading to signaling and transcription of a reporter gene, (2) the homodimerization of the cytoplasmic tail of the Fas receptor thereby leading to cell-specific apoptosis (programmed cell death) and (3) the heterodimerization of a DNA-binding domain (Gal4) and a transcription-activation domain (VP16) thereby leading to direct transcription of a reporter gene. Regulated intracellular protein association with our cell permeable, synthetic ligands offers new capabilities in biological research and medicine, in particular, in gene therapy. Using gene transfer techniques to introduce our artificial receptors, one can turn on or off the signaling pathways that lead to the overexpression of therapeutic proteins by administering orally active "dimerizers" or "de-dimerizers", respectively. Since cells from different recipients can be configured to have the pathway overexpress different therapeutic proteins for use in a variety of disorders, the dimerizers have the potential to serve as "universal drugs". They can also be viewed as cell permeable, organic replacements for therapeutic antisense agents or for proteins that would otherwise require intravenous injection or intracellular expression (e.g., the LDL receptor or the CFTR protein).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 13 OF 38 USPATFULL

ACCESSION NUMBER: 2000:1861 USPATFULL
TITLE: Regulated transcription of targeted genes and other biological events
INVENTOR(S): Crabtree, Gerald R., Woodside, CA, United States
Schreiber, Stuart L., Cambridge, MA, United States
Spencer, David M., Los Altos, CA, United States
Wandless, Thomas J., Cambridge, MA, United States
Belshaw, Peter, Cambridge, MA, United States
PATENT ASSIGNEE(S): Board of Trustees of Leland Stanford Jr. University, Stanford, CA, United States (U.S. corporation)
President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6011018		20000104

APPLICATION INFO.: US 1993-87716 19980529 (9)
RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-388653, filed on 14 Feb 1995, now patented, Pat. No. US 5869337 which is a continuation-in-part of Ser. No. US 1994-196043, filed on 11 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-179748, filed on 7 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-32977, filed on 16 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-17931, filed on 11 Feb 1993, now abandoned And a continuation-in-part of Ser. No. US 1994-332597, filed on 19 Aug 1994, now patented, Pat. No. US 5834266 which is a continuation-in-part of Ser. No. US 1994-179143, filed on 7 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-93499, filed on 16 Jul 1993, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Elliott, George C.
ASSISTANT EXAMINER: Schwartzman, Robert
LEGAL REPRESENTATIVE: Bernstein, David L., Hausdorff, Sharon F., Vincent, Matthew P.

NUMBER OF CLAIMS: 70
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 36 Drawing Figure(s); 36 Drawing Page(s)
LINE COUNT: 4687

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Dimerization and oligomerization of proteins are general biological control mechanisms that contribute to the activation of cell membrane receptors, transcription factors, vesicle fusion proteins, and other classes of intra- and extracellular proteins. We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins. In principle, any two target proteins can be induced to associate by treating the cells or organisms that harbor them with cell permeable, synthetic ligands. To illustrate the practice of this invention, we have induced: (1) the intracellular aggregation of the cytoplasmic tail of the .zeta. chain of the T cell receptor (TCR)-CD3 complex thereby leading to signaling and transcription of a reporter gene, (2) the homodimerization of the cytoplasmic tail of the Fas receptor thereby leading to cell-specific apoptosis (programmed cell death) and (3) the heterodimerization of a DNA-binding domain (Gal4) and a transcription-activation domain (VP16) thereby leading to direct transcription of a reporter gene. Regulated intracellular protein association with our cell permeable, synthetic ligands offers new capabilities in biological research and medicine, in particular, in gene therapy. Using gene transfer techniques to introduce our artificial receptors, one can turn on or off the signaling pathways that lead to the overexpression of therapeutic proteins by administering orally active "dimerizers" or "de-dimerizers", respectively. Since cells from different recipients can be configured to have the pathway overexpress different therapeutic proteins for use in a variety of disorders, the dimerizers have the potential to serve as "universal drugs". They can also be viewed as cell permeable, organic replacements for therapeutic antisense agents or for proteins that would otherwise require intravenous injection or intracellular expression (e.g., the LDL receptor or the CFTR protein).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 14 OF 38 USPATEFULL
ACCESSION NUMBER: 1999:155696 USPATEFULL
TITLE: Regulated apoptosis
INVENTOR(S): Crabtree, Gerald R., Woodside, CA, United States
Schreiber, Stuart L., Cambridge, MA, United States

PATENT ASSIGNEE(S): Spencer, David M., Los Altos, CA, United States
Wandless, Thomas J., Cambridge, MA, United States
Belshaw, Peter, Somerville, MA, United States
Board of Trustees of the Leland S. Stanford, Jr. Univ.,
Stanford, CA, United States (U.S. corporation)
President and Fellows of Harvard College, Cambridge,
MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5994313		19991130
APPLICATION INFO.:	US 1995-483393		19950637 (3)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-092597, filed on 18 Aug 1994, now patented, Pat. No. US 5834266 which is a continuation-in-part of Ser. No. US 1994-196043, filed on 14 Feb 1994, now abandoned And Ser. No. US 1994-179143, filed on 17 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-93499, filed on 16 Jul 1993, now abandoned, said Ser. No. US 196043 which is a continuation-in-part of Ser. No. US 1994-179743, filed on 7 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-92977, filed on 16 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-17931, filed on 12 Feb 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Elliott, George C.		
ASSISTANT EXAMINER:	Schwartzman, Robert		
LEGAL REPRESENTATIVE:	Bernstein, David L., Hausdorff, Sharon F., Vincent, Matthew F.		
NUMBER OF CLAIMS:	48		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	32 Drawing Figure(s); 34 Drawing Page(s)		
LINE COUNT:	4791		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins and disclose methods and materials for using that procedure to regulatably initiate cell-specific apoptosis (programmed cell death) in genetically engineered cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

1131 ANSWER 15 OF 38 USPATFULL
ACCESSION NUMBER: 1999:141886 USPATFULL
TITLE: **Cyclosporins**
INVENTOR(S): Ko, Soo Young, London, United Kingdom
Kobel, Hans, Basel, Switzerland
Besemer-Rosenwirth, Brigitte, Modling, Austria
Seebach, Dieter, Zurich, Switzerland
Traber, Rene P., Basel, Switzerland
Wenger, Roland, Riehen, Switzerland
Bollinger, Pietro, Bottmingen, Switzerland
PATENT ASSIGNEE(S): Novartis AG, Basel, Switzerland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5981479		19991109
APPLICATION INFO.:	US 1998-84709		19980526 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-42731E, filed on 24 Apr 1995, now patented, Pat. No. US 5767069		

NUMBER	DATE

PRIORITY INFORMATION: GB 1990-23859 19901102
GB 1990-23870 19901105
GB 1990-23871 19901105
GB 1990-23872 19901105
GB 1991-16836 19910805

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Tsang, Cecilia J.
LEGAL REPRESENTATIVE: Lopez, Gabriel, Furman, Diane E.
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 341

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB It has been found that nonimmunosuppressive, cyclophilin-binding **cyclosporins** are useful in the treatment and prevention of AIDS and AIDS-related disorders. Such **cyclosporins** include novel Cyclosporin derivatives modified at the 4- and/or 5-positions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

LIB1 ANSWER 16 OF 38 USPATEFULL

ACCESSION NUMBER: 1992:19001 USPATEFULL
TITLE: Regulated transcription of targeted genes and other biological events
INVENTOR(S): Drabtree, Gerald R., Woodside, CA, United States
Schreiber, Stuart L., Cambridge, MA, United States
Spencer, David M., Los Altos, CA, United States
Wandless, Thomas J., Cambridge, MA, United States
Belshaw, Peter, Cambridge, MA, United States
PATENT ASSIGNEE(S): President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)
Board of Trustees of Leland S. Stanford Jr. University, Stanford, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5869337		19990209
APPLICATION INFO.:	US 1995-388653		19950214 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-196043, filed on 11 Feb 1994 And Ser. No. US 1994-292597, filed on 18 Aug 1994, now patented, Pat. No. US 5834266, each Ser. No. US which is a continuation-in-part of Ser. No. US 1994-179748, filed on 7 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-92977, filed on 16 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-17931, filed on 12 Feb 1993, now abandoned, said Ser. No. US 292597 which is a continuation-in-part of Ser. No. US 1994-179148, filed on 7 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-93499, filed on 16 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 17931		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Elliott, George C.
ASSISTANT EXAMINER: Schwartzman, Robert
LEGAL REPRESENTATIVE: Vincent, Matthew P., Clauss, Isabelle M. Foley, Hoag & Eliot LLP
NUMBER OF CLAIMS: 165
EXEMPLARY CLAIM: 35
NUMBER OF DRAWINGS: 37 Drawing Figure(s); 36 Drawing Page(s)
LINE COUNT: 4716

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Dimerization and oligomerization of proteins are general biological

control mechanisms that contribute to the activation of cell membrane receptors, transcription factors, vesicle fusion proteins, and other classes of intra- and extracellular proteins. We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins. In principle, any two target proteins can be induced to associate by treating the cells or organisms that harbor them with cell permeable, synthetic ligands. To illustrate the practice of this invention, we have induced: (1) the intracellular aggregation of the cytoplasmic tail of the zeta chain of the T cell receptor (TCR)-CD3 complex thereby leading to signaling and transcription of a reporter gene, (2) the homodimerization of the cytoplasmic tail of the Fas receptor thereby leading to cell-specific apoptosis (programmed cell death) and (3) the heterodimerization of a DNA-binding domain (Gal4) and a transcription-activation domain (VP16) thereby leading to direct transcription of a reporter gene. Regulated intracellular protein association with our cell permeable, synthetic ligands offers new capabilities in biological research and medicine, in particular, in gene therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 17 OF 38 USPTFULL

ACCESSION NUMBER: 1998:138709 USPTFULL

TITLE: Regulated apoptosis

INVENTOR(S): Crabtree, Gerald R., Woodside, CA, United States
Schreiber, Stuart L., Cambridge, MA, United States
Spencer, David M., Los Altos, CA, United States
Wandless, Thomas J., Cambridge, MA, United States
Belshaw, Peter, Somerville, MA, United States
PATENT ASSIGNEE(S): President & Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)
Board of Trustees of Leland Stanford Jr. University, Stanford, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5834266		19981110
APPLICATION INFO.:	US 1994-292597		19940818 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-179143, filed on 7 Jan 1994, now abandoned And Ser. No. US 1994-179748, filed on 7 Jan 1994 which is a continuation-in-part of Ser. No. US 1993-92977, filed on 16 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-17931, filed on 12 Feb 1993, now abandoned, said Ser. No. US 179143 which is a continuation-in-part of Ser. No. US 1993-93499, filed on 16 Jul 1993		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Elliott, George C.		
ASSISTANT EXAMINER:	Schwartzman, Robert		
LEGAL REPRESENTATIVE:	Vincent, Matthew P., Clauss, Isabelle M.Foley, Hoag & Eliot LLP		
NUMBER OF CLAIMS:	235		
EXEMPLARY CLAIM:	118		
NUMBER OF DRAWINGS:	35 Drawing Figure(s); 34 Drawing Page(s)		
LINE COUNT:	5099		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins and disclose methods and materials for using that procedure to regulatably initiate cell-specific apoptosis (programmed cell death) in genetically engineered cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L131 ANSWER 18 OF 38 USPATFULL

ACCESSION NUMBER: 1993:134626 USPATFULL

TITLE: Regulated transcription of targeted genes and other biological events

INVENTOR(S): Traostree, Gerald R., Woodside, CA, United States
Schreiber, Stuart L., Cambridge, MA, United States
Spencer, David M., Los Altos, CA, United States
Wandless, Thomas J., Cambridge, MA, United States
Belshaw, Peter, Cambridge, MA, United States

PATENT ASSIGNEE(S): President & Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)
Board of Trustees of Leland S. Stanford, Jr. University, Stanford, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5830462		19931103
APPLICATION INFO.:	US 1995-478386		19950607 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-388653, filed on 14 Feb 1995 And a continuation-in-part of Ser. No. US 1994-292597, filed on 13 Aug 1994 which is a continuation-in-part of Ser. No. US 1994-179748, filed on 7 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-92977, filed on 16 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-17931, filed on 12 Feb 1993, now abandoned, said Ser. No. US 388653 which is a continuation-in-part of Ser. No. US 1994-196043, filed on 11 Feb 1994 which is a continuation-in-part of Ser. No. US 179748 which is a continuation-in-part of Ser. No. US 92977 which is a continuation-in-part of Ser. No. US 17931		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Elliott, George C.		
ASSISTANT EXAMINER:	Schwartzman, Robert		
LEGAL REPRESENTATIVE:	Vincent, Matthew P., Clauss, Isabelle M.Foley, Hoag & Eliot LLP		
NUMBER OF CLAIMS:	127		
EXEMPLARY CLAIM:	34		
NUMBER OF DRAWINGS:	37 Drawing Figure(s); 36 Drawing Page(s)		
LINE COUNT:	4591		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Dimerization and oligomerization of proteins are general biological control mechanisms that contribute to the activation of cell membrane receptors, transcription factors, vesicle fusion proteins, and other classes of intra- and extracellular proteins. We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins. In principle, any two target proteins can be induced to associate by treating the cells or organisms that harbor them with cell permeable, synthetic ligands. To illustrate the practice of this invention, we have induced: (1) the intracellular aggregation of the cytoplasmic tail of the .zeta. chain of the T cell receptor (TCR)-CD3 complex thereby leading to signaling and transcription of a reporter gene, (2) the homodimerization of the cytoplasmic tail of the Fas receptor thereby leading to cell-specific apoptosis (programmed cell death) and (3) the heterodimerization of a DNA-binding domain (Gal4) and a transcription-activation domain (VP16) thereby leading to direct transcription of a reporter gene.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 19 OF 38 USPATFULL

ACCESSION NUMBER: 1998:68992 USPATFULL
 TITLE: **Cyclosporins**
 INVENTOR(S): Ko, Soo Young, London, Great Britain
 Kobel, Hans, Basel, Switzerland
 Besemer-Rosenwirth, Brigitte, Modling, Austria
 Seebach, Dieter, Zurich, Switzerland
 Traber, Rene P., Basel, Switzerland
 Wenger, Roland, Riehen, Switzerland
 Bollinger, Pietro, Bottmingen, Switzerland
 PATENT ASSIGNEE(S): Novartis AG, Basel, Switzerland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5767069		19980616
APPLICATION INFO.:	US 1995-427312		19950424 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-232795, filed on 25 Apr 1994, now abandoned which is a continuation of Ser. No. US 1993-57067, filed on 3 May 1993, now abandoned which is a continuation of Ser. No. US 1991-785959, filed on 31 Oct 1991, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1990-23859	19901100
	GB 1990-23970	19901105
	GB 1990-23971	19901105
	GB 1990-23972	19901105
	GB 1991-16836	19910805
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Achutamurthy, Pennathapura	
ASSISTANT EXAMINER:	Wessendorf, T. D.	
LEGAL REPRESENTATIVE:	Mathias, Marla J., McGovern, Thomas O.	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 3 Drawing Page(s)	
LINE COUNT:	779	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Nonimmunosuppressant **cyclosporin** derivatives having cyclophilin-binding activity, for example, the compound, [Melle].sup.4 -ciclosporin, are useful in inhibiting HIV-1 replication in treating AIDS and AIDS related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 20 OF 38 USPATFULL
 ACCESSION NUMBER: 97:56636 USPATFULL
 TITLE: O-acylated **cyclosporins**
 INVENTOR(S): Boelsterli, Johann Jakob, Buus, Switzerland
 Eberle, Marcel Karl, Fiehen, Switzerland
 Naef, Reto, Rheinfelden, Switzerland
 Payne, Trevor Glyn, Berne, Switzerland
 PATENT ASSIGNEE(S): Sandoz Ltd., Basel, Switzerland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5643870		19970701
APPLICATION INFO.:	US 1993-23525		19930226 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1992-4466	19920302
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Tsang, Cecilia	

ASSISTANT EXAMINER: Marshall, S. G.
LEGAL REPRESENTATIVE: Honor, Robert S., Kassenoff, Melvyn M., McGovern,
Thomas C.
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 770

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A **cyclosporin** of the formula ##STR1## wherein A is a residue
of the formula ##STR2## wherein R is hydrogen, C.sub.1-3 **alkyl**
, C.sub.1-3 alkoxy or C.sub.1-3 alkylthio; halo-substituted-C.sub.1-3
alkyl, -C.sub.1-3 alkoxy or -C.sub.1-3 alkylthio;
hydroxy-substituted-C.sub.1-3 **alkyl**, -C.sub.2-3 alkoxy or
-C.sub.2-3 alkylthio; or amino or mono- or di-(C.sub.1-2 **alkyl**
)-amino,

X is oxygen or sulphur,

--x--y-- is --CH.dbd.CH-- (trans) or --CH.sub.2 --CH.sub.2 --,

B is -.alpha.Abu-, -Val-, -Thr- or -Nva- and

Q is -(D)Ala-; -(D)Ser ; -[O-(2-hydroxyethyl) (D)Ser]-; or
-[O-acyl (D)Ser]- or -[O-(2-acyloxy ethyl) (D)Ser]-

in which the acyl residue is physiologically hydrolysable and
acceptable, are useful in the topical treatment of asthma.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 21 OF 38 USPTFULL

ACCESSION NUMBER: 96:50887 USPTFULL

TITLE: **Cyclosporins** and their use as pharmaceuticals

INVENTOR(S): Bollinger, Pietro, Bottmingen, Switzerland

Bolsterli, Johann J., Buus, Switzerland

Payne, Trevor G., Bern; all of, Switzerland

PATENT ASSIGNEE(S): Sandoz Ltd., Basel, Switzerland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5525590		19960611
APPLICATION INFO.:	US 1994-337346		19941110 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-67274, filed on 24 May 1993, now abandoned which is a continuation of Ser. No. US 1992-874676, filed on 27 Apr 1992, now abandoned which is a continuation of Ser. No. US 1991-704758, filed on 23 May 1991, now abandoned which is a continuation of Ser. No. US 1988-208422, filed on 17 Jun 1989, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1987-14090	19870617
	GB 1987-14093	19870617
	GB 1987-14098	19870617
	GB 1987-14100	19870617
	GB 1987-14115	19870617
	GB 1987-14118	19870617
	GB 1987-14119	19870617
	GB 1987-14125	19870617

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted

PRIMARY EXAMINER: Russel, Jeffrey E.

LEGAL REPRESENTATIVE: Honor, Robert S., Kassenoff, Melvyn M., McGovern,
Thomas C.

NUMBER OF CLAIMS: 5

EXEMPLARY CLAIM: 1
LINE COUNT: 2011
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB **Cyclosporins** wherein the residue at the 1-position (typically -MeBmt- or -dihydro-MeBmt-) is 3'-O-acylated or 3'-oxo or -C.sub.1-4 alkoxyimino substituted, or wherein the residue at the 2-position is .beta.-O-acyl or .beta.-oxo substituted, or wherein the residue at the 2-position is -Ile-, or wherein the residue at the 11-position is -MeAls-, -MeIle- or -MealloIle- as well as various naturally occurring **cyclosporins**/dihydro-derivatives thereof, are useful in reversing resistance to chemotherapy, in particular resistance to cytostatic or anti-neoplastic therapy. Various of these **cyclosporins** and intermediates for their production are novel. Intermediates wherein the residue (e.g. -MeBmt-, -dihydro-MeBmt- etc.) at the 1-position is 8'-alkoxy or 7'-desmethyl-7'-hydrocarbyl substituted are novel and useful as immunosuppressants, anti-inflammatory and anti-parasitic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 22 OF 38 USPATEFULL
ACCESSION NUMBER: 93:57009 USPATEFULL
TITLE: Immunosuppressive fluorinated **cyclosporin** analogs
INVENTOR(S): Durette, Philippe L., New Providence, NJ, United States
Pessolano, Arsenio A., Colonia, NJ, United States
Kollonitsch, Janos, Westfield, NJ, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5027467		19930713
APPLICATION INFO.:	US 1991-693783		19910429 (7)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1989-298712, filed on 19 Jan 1989, now abandoned which is a continuation-in-part of Ser. No. US 1987-81255, filed on 3 Aug 1987, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Chan, Y. Christina		
LEGAL REPRESENTATIVE:	Panzer, Curtis C., Speer, Raymond M.		
NUMBER OF CLAIMS:	2		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1022		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB New immunosuppressive **cyclosporin** analogs are disclosed having one or more fluorinated amino acids. These analogs may also have a "C-9 amino acid" wherein the double bond is replaced by a heteroatom such as sulfur or oxygen.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 23 OF 38 USPATEFULL
ACCESSION NUMBER: 93:42149 USPATEFULL
TITLE: **Synthesis** of novel immunosuppressive **cyclosporin** analogs with modified amino acids at position-3
INVENTOR(S): Patchett, Arthur A., Westfield, NJ, United States
Taub, David, Metuchen, NJ, United States
Goepelman, Robert T., Linden, NJ, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 5214130 19930525
 APPLICATION INFO.: US 1991-744039 19910812 (7)
 RELATED APPLN. INFO.: Division of Ser. No. US 1990-485920, filed on 27 Feb 1990, now patented, Pat. No. US 5122511
 DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Lee, Lester L.
 ASSISTANT EXAMINER: Davenport, A. M.
 LEGAL REPRESENTATIVE: Panzer, Curtis C., Speer, Raymond M.
 NUMBER OF CLAIMS: 6
 EXEMPLARY CLAIM: 1
 LINE COUNT: 637

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB New immunosuppressive **cyclosporin** analogs are disclosed consisting of [dehydro-Ala].sup.8 **cyclosporins** and derived therefrom **cyclosporins** having a sulfur containing amino acid at position-8.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 24 OF 38 USPATEFULL

ACCESSION NUMBER: 92:42045 USPATEFULL
 TITLE: Immunosuppressive **cyclosporin** analogs with modified amino acids at position-8
 INVENTOR(S): Patchett, Arthur A., Westfield, NJ, United States
 Taub, David, Metuchen, NJ, United States
 Goegelman, Robert T., Linden, NJ, United States
 PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5122511		19920616
APPLICATION INFO.:	US 1990-485920		19900227 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Lee, Lester L.		
ASSISTANT EXAMINER:	Davenport, A. M.		
LEGAL REPRESENTATIVE:	Panzer, Curtis C., Pfeiffer, Hesna J.		
NUMBER OF CLAIMS:	11		
EXEMPLARY CLAIM:	1		
LINE COUNT:	670		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB New immunosuppressive **cyclosporin** analogs are disclosed consisting of [dehydro-Ala].sup.8 **cyclosporins** and derived therefrom **cyclosporins** having a sulfur containing amino acid at position-8.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 25 OF 38 USPATEFULL

ACCESSION NUMBER: 92:42742 USPATEFULL
 TITLE: **Cyclosporin** peptolides having an .alpha.-hydroxycarboxylic acid at position 8
 INVENTOR(S): Dreyfuss, Michael M., Basel, Switzerland
 Schreier, Max H., Basel, Switzerland
 Tscherter, Hans, Allschwil, Switzerland
 PATENT ASSIGNEE(S): Sandoz Ltd., Basel, Switzerland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5116816		19920526
APPLICATION INFO.:	US 1988-209680		19880620 (7)

	NUMBER	DATE
PRIORITY INFORMATION:	CH 1987-2317	19870619
	CH 1987-2517	19870702
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Chan, Christina	
LEGAL REPRESENTATIVE:	Sharkin, Gerald D., Honor, Robert S., McGovern, Thomas	
	O.	
NUMBER OF CLAIMS:	2	
EXEMPLARY CLAIM:	1,9	
LINE COUNT:	511	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Cyclic peptolides having the structure of a **cyclosporin** in which one amide linkage is replaced by an ester linkage are obtained by fermentation of fungal strains of the genus *Cylindrotrichum* Bonorden, or by cyclization of a hydroxy-undecapeptide. The cyclic peptolides have immunosuppressive, anti-inflammatory and anti-parasitic properties.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 26 OF 38 USPTFLL

ACCESSION NUMBER: 90:25853 USPTFLL
 TITLE: Novel 6-position **cyclosporin** analogs as non-immunosuppressive antagonists of **cyclosporin** binding to cyclophilin
 INVENTOR(S): Dumont, Francis J., Rahway, NJ, United States
 Durette, Philippe L., New Providence, NJ, United States
 Fessolano, Arsenio A., Colonia, NJ, United States
 Boger, Joshua S., Westfield, NJ, United States
 Sigal, Nolan H., Westfield, NJ, United States
 PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4914188		19900403
APPLICATION INFO.:	US 1987-121827		19871116 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Lee, Lester L.		
ASSISTANT EXAMINER:	Chan, Christina		
LEGAL REPRESENTATIVE:	Diprima, Joseph F., North, Robert J., Panzer, Curtis C.		
NUMBER OF CLAIMS:	3		
EXEMPLARY CLAIM:	1		
LINE COUNT:	691		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel **cyclosporin** analogs containing a MeAla or MeAib residue at the 6-position of the cyclic undecapeptide have been synthesized and found unexpectedly to exhibit antagonistic activity toward **cyclosporin** A binding to its cytosolic protein receptor, cyclophilin, without being immunosuppressive.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 27 OF 38 USPTFLL

ACCESSION NUMBER: 88:59156 USPTFLL
 TITLE: Novel **cyclosporins**
 INVENTOR(S): Seekach, Dieter, Zurich, Switzerland
 PATENT ASSIGNEE(S): Sandoz Ltd., Basel, Switzerland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4771122		19880913
APPLICATION INFO.:	US 1987-103990		19871001 (7)

RELATED APPLN. INFO.: Division of Ser. No. US 1986-837434, filed on 7 Mar 1986, now patented, Pat. No. US 4703033

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1985-11029	19850501
	GB 1985-5230	19850511
	GB 1986-2370	19860131
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Phillips, Delbert F.	
LEGAL REPRESENTATIVE:	Sharkin, Gerald D., Honor, Robert S., McGovern, Thomas O.	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1157	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Cyclosporins e.g. of formula II ##STF1## in which X is -MeBmt- or -dihydro-MeBmt- and

Y is -.alpha.Abu-, -Thr-, -Val- or -Nva-,

wherein the residue at the 3-position, i.e. the residue Z in formula II, is an optically active, .alpha.-N-methylated .alpha.-amino acid residue of the (D)-configuration, possess pharmaceutical, in particular immunosuppressive, anti-inflammatory and anti-parasitic activity, Intermediate **cyclosporin** poly-anions having a de-protonated sarcosyl residue at the 3-position, e.g. polyanions of **cyclosporins** of formula II above wherein X and Y have the meanings given above and Z is -Sar-, in which the said residue Z is de-protonated, are also novel and part of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 28 OF 38 USPATFULL
ACCESSION NUMBER: 88:52079 USPATFULL
TITLE: Novel **cyclosporins**
INVENTOR(S): Wenger, Roland, Riehen, Switzerland
PATENT ASSIGNEE(S): Sandoz Ltd., Basel, Switzerland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4764503		19880816
APPLICATION INFO.:	US 1987-49746		19870513 (7)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1986-932760, filed on 19 Nov 1986, now abandoned which is a continuation of Ser. No. US 1985-713259, filed on 19 Mar 1985, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Phillips, Delbert F.		
LEGAL REPRESENTATIVE:	Sharkin, Gerald D., Honor, Robert S., McGovern, Thomas O.		
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	1		
LINE COUNT:	888		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB **Cyclosporins** wherein the amino acid residue at the 8-position is a (D)-acyloxy-.alpha.-amino acid residue, typically of formula ##STR1## wherein X=--MeBmt-- or --dihydro--MeBmt--, Y=--.alpha.Abu--, --Ala--, --Thr--, --Val-- or --Nva--, Z=--Val-- or --Nva-- and Q=R.sub.1 --CO--O--CH(R.sub.2)--CH(CO--)--NH-- wherein R.sub.1 =H, C.sub.1-4 **alkyl** or phenyl and R.sub.2 =H or CH.sub.3, possess immunosuppressive, anti-inflammatory and anti-parasitic activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

LI81 ANSWER 29 OF 38 USPATEFULL
ACCESSION NUMBER: 87:75000 USPATEFULL
TITLE: Novel **cyclosporins**
INVENTOR(S): Seebach, Dieter, Zurich, Switzerland
PATENT ASSIGNEE(S): Sandoz Ltd., Basel, Switzerland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4703033		19871027
APPLICATION INFO.:	US 1986-837434		19860307 (6)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1985-6230	19850311
	GB 1985-11029	19850501
	GB 1986-2370	19860131

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Phillips, Delbert K.
LEGAL REPRESENTATIVE: Sharkin, Gerald D., Honor, Robert S., McGovern, Thomas O.
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
LINE COUNT: 1262

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB **Cyclosporins** e.g. of formula II ##STR1## in which X is -
MeBmt- or -dihydro-**MeBmt-** and

Y is -.alpha.Abu-, -Thr-, -Val- or -Nva-,

wherein the residue at the 3-position, i.e. the residue Z in formula II, is an optically active, .alpha.-N-methylated .alpha.-amino acid residue of the (D)-configuration, possess pharmaceutical, in particular immunosuppressive, anti-inflammatory and anti-parasitic activity. Intermediate **cyclosporin** poly-anions having a de-protonated sarcosyl residue at the 3-position, e.g. polyanions of **cyclosporins** of formula II above wherein X and Y have the meanings given above and Z is -Sar-, in which the said residue Z is de-protonated, are also novel and part of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

LI81 ANSWER 30 OF 38 USPATEFULL
ACCESSION NUMBER: 87:6447 USPATEFULL
TITLE: Novel **cyclosporins**
INVENTOR(S): Wenger, Roland, Riehen, Switzerland
Traber, Rene P., Basel, Switzerland
Kobel, Hans, Basel, Switzerland
Hofmann, Hans, Ettingen, Switzerland
PATENT ASSIGNEE(S): Sandoz Ltd., Basel, Switzerland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4639434		19870127
APPLICATION INFO.:	US 1985-713429		19850319 (6)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1984-7613	19840323
	GB 1984-11922	19840510

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Phillips, Delbert R.

LEGAL REPRESENTATIVE: Sharkin, Gerald D., Honor, Robert S., McGovern, Thomas
D.
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
LINE COUNT: 980
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB **Cyclosporins** wherein the amino acid residue at the 2-position is a (D)-acyloxy-.alpha.-amino acid residue, typically of formula ##STR1## wherein X=**MeBmt**- or -dihydro-**MeBmt** , Y=-.alpha.Abu-, -Ala-, -Thr , -Val- or -Nva-, Z=-Val- or -Nva- and Q=R.sub.1 --CO--O--CH(R.sub.2)--CH(CO--)--NH--wherein R.sub.1 =H, C.sub.1-4 **alkyl** or phenyl and R.sub.2 =H or CH.sub.3, possess immunosuppressive, anti-inflammatory and anti-parasitic activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 31 OF 33 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2001072299 PCTFULL EP 20020822
TITLE (ENGLISH): TAXANE-BASED COMPOSITIONS AND METHODS OF USE
TITLE (FRENCH): COMPOSITIONS A BASE DE TAXANE ET PROCEDES D'UTILISATION
INVENTOR(S): ZHANG, Kai; SMITH, Gregory, A.; GUTIERREZ-ROCA, Jose, C.
PATENT ASSIGNEE(S): BAKER NORTON PHARMACEUTICALS, INC.; ZHANG, Kai; SMITH, Gregory, A.; GUTIERREZ-ROCA, Jose, C.
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
--------	------	------

WO 2001072299	A1	20011004
---------------	----	----------

DESIGNATED STATES

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL
IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG
MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ
TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ
SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH
CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ
CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2001-US9382 A 20010323
PRIORITY INFO.: US 2000-60/191,802 20000324

ABEN Disclosed are taxane-based compositions and methods of using the same to achieve target blood levels of a taxane in a mammal, e.g., to treat taxane-responsive malignant and non-malignant diseases. Compositions of the invention exhibit long-term stability and overall palatability. Also disclosed are methods for using the compositions as analytical tools for pharmacokinetic studies.

ABFR L'invention concerne des compositions a base de taxane et des procedes permettant d'utiliser ces compositions pour atteindre des concentrations sanguines cibles de taxane chez un mammifere, par exemple, pour traiter des maladies malignes et des maladies benignes. Les compositions decrites dans cette invention presentent une stabilite a long terme et une sapidite globale. L'invention concerne egalement des procedes permettant d'utiliser ces compositions comme outils d'analyse dans des etudes pharmacocinetiques.

L181 ANSWER 32 OF 38 EUROPATEFULL COPYRIGHT 2002 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 577544 EUROPATEFULL EW 199401 FS OS STA B
TITLE: Novel **cyclosporins** having modifications at position 1.
Neue Cyclosporine mit Modifikationen in Position-1.
Nouvelles cyclosporines modifiees en position 1.
INVENTOR(S): Boelsterli, Johann Jakob, Brunngasse 4, CH-4463 Buus, CH;

Eberle, Marcel Karl, Bahnhofstrasse 52, CH-4125 Riehen, CH;
 Naef, Reto, Marktgasse 8a, CH-4310 Rheinfelden, CH;
 Payne, Trevor Glyn, Dalmazirain 26, CH-3005 Berne, CH
 PATENT ASSIGNEE(S): SANDOZ LTD., Lichtstrasse 35, CH-4002 Basel, CH, in BE, CH, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE;
 SANDOZ-PATENT-GMBH, Humboldtstrasse 3, D-79539 Loerrach, DE, in DE;
 SANDOZ-ERFINDUNGEN Verwaltungsgesellschaft m.b.H., Brunner Strasse 59, A-1230 Wien, AT, in AT
 PATENT ASSIGNEE NO: 201940; 498060; 498070
 OTHER SOURCE: ESP1994002 EP 0577544 A1 940105
 SOURCE: Wila-EPS-1994-H01-T1a
 DOCUMENT TYPE: Patent
 LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
 DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R NL; R PT; R SE
 PATENT INFO.PUB.TYPE: EPAL EUROPAEISCHE PATENTANMELDUNG
 PATENT INFORMATION:

	PATENT NO	KIND	DATE
	EP 577544	A1	19940105
'OFFENLEGUNGS' DATE:			19940105
APPLICATION INFO.:	EP 1993-810113		19930322
PRIORITY APPLN. INFO.:	GB 1992-4466		19920302

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 577544 EUROPATEFULL EW 199651 FS PS
 TITLE: Novel **cyclosporins** having modifications at position 1.
 Neue Cyclosporine mit Modifikationen in Position 1.
 Nouvelles cyclosporines modifiees en position 1.
 INVENTOR(S): Boelsterli, Johann Jakob, Brunnegasse 4, CH-4463 Buus, CH;
 Eberle, Marcel Karl, Bahnhofstrasse 52, CH-4125 Riehen, CH;
 Naef, Reto, Marktgasse 8a, CH-4310 Rheinfelden, CH;
 Payne, Trevor Glyn, Dalmazirain 26, CH-3005 Berne, CH
 PATENT ASSIGNEE(S): SANDOZ LTD., Lichtstrasse 35, 4002 Basel, CH, in BE, CH, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE;
 SANDOZ-PATENT-GMBH, Humboldtstrasse 3, 79539 Loerrach, DE, in DE;
 SANDOZ-ERFINDUNGEN Verwaltungsgesellschaft m.b.H., Brunner Strasse 59, 1235 Wien, AT, in AT
 PATENT ASSIGNEE NO: 201940; 498060; 498070
 OTHER SOURCE: EPB1996077 EP 0577544 B1 961218
 SOURCE: Wila-EPS-1996-H51-T1
 DOCUMENT TYPE: Patent
 LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
 DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R NL; R PT; R SE
 PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT
 PATENT INFORMATION:

	PATENT NO	KIND	DATE
	EP 577544	B1	19961218
'OFFENLEGUNGS' DATE:			19940105
APPLICATION INFO.:	EP 1993-810113		19930322
PRIORITY APPLN. INFO.:	GB 1992-4466		19920302
REFERENCE PAT. INFO.:	EP 414632 A		US 4996193 A

L181 ANSWER 33 OF 38 EUROPATEFULL COPYRIGHT 2002 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 484281 EUROPATFULL EW 199219 FS 03 STA B
 TITLE: **Cyclosporins.**
 Zyklosporine.
 Cyclosporines.
 INVENTOR(S): Ko, Soo Young, Flat 5, 42 Belsize Park Gardens, London
 NW3 4LY, GB;
 Kibel, Hans, Weissensteinstrasse 1, CH-4059 Basle, CH;
 Rosenwirth, Brigitte, C. Zwillinggasse 17, A-2340
 Moedling, AT;
 Seebach, Dieter, Orellistrasse 3, CH-8044 Zuerich, CH;
 Traber, Rene P., Hirzbodenpark 20, CH-4052 Basle, CH;
 Wenger, Roland, Grenzacherweg 45, CH-4125 Biehlen, CH;
 Bollinger, Pietro, Gustackerstrasse 56, CH-4103
 Bottmingen, CH
 PATENT ASSIGNEE(S): SANDOZ LTD., Lichtstrasse 35, CH-4002 Basel, CH, in BE,
 CH, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE;
 SANDOZ-PATENT-GMBH, Humboldtstrasse 3, W-7850 Loerrach,
 DE, in DE;
 SANDOZ ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H.,
 Brunner Strasse 59, A-1235 Vienna, AT, in AT
 PATENT ASSIGNEE NO: 201240; 498060; 1297990
 OTHER SOURCE: ESP1992035 EP 0484281 A2 920506
 SOURCE: Wila-EP3-1992-H19-T1
 DOCUMENT TYPE: Patent
 LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
 DESIGNATED STATES: F AT; F BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R
 IT; R LI; R LU; R NL; R SE
 PATENT INFO.PUB.TYPE: EPAL EUROPAEISCHE PATENTANMELDUNG
 PATENT INFORMATION:

	PATENT NO	KIND DATE
	EP 484281	A2 19920506
'OFFENLEGUNGS' DATE:		19920506
APPLICATION INFO.:	EP 1991-810841	19911030
PRIORITY APPLN. INFO.:	GB 1990-23859	19901102
	GB 1990-23972	19901105
	GB 1990-23970	19901105
	GB 1990-23971	19901105
	GB 1991-16836	19910805

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 484281 EUROPATFULL EW 199705 FS PS
 TITLE: **Cyclosporins.**
 Zyklosporine.
 Cyclosporines.
 INVENTOR(S): Ko, Soo Young, Flat 5, 42 Belsize Park Gardens, London
 NW3 4LY, GB;
 Kibel, Hans, Weissensteinstrasse 1, CH-4059 Basle, CH;
 Rosenwirth, Brigitte, C. Zwillinggasse 17, A-2340
 Moedling, AT;
 Seebach, Dieter, Orellistrasse 3, CH-8044 Zuerich, CH;
 Traber, Rene P., Hirzbodenpark 20, CH-4052 Basle, CH;
 Wenger, Roland, Grenzacherweg 45, CH-4125 Biehlen, CH;
 Bollinger, Pietro, Gustackerstrasse 56, CH-4103
 Bottmingen, CH
 PATENT ASSIGNEE(S): SANDOZ LTD., Lichtstrasse 35, 4002 Basel, CH, in BE, CH,
 DK, ES, FR, GB, GR, IT, LI, LU, NL, SE;
 SANDOZ-PATENT-GMBH, Humboldtstrasse 3, 79539 Loerrach,
 DE, in DE;
 SANDOZ ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H.,
 Brunner Strasse 59, 1235 Wien, AT, in AT
 PATENT ASSIGNEE NO: 201240; 498060; 1297990
 OTHER SOURCE: EPB1997009 EP 0484281 B1 970129

SOURCE: Wila-EPS-1997-H05-T1
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: E AT; R BE; R CH; F DE; R DK; R ES; R FR; R GB; R GR; R IT; R LI; R LU; R NL; R SE
PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT
PATENT INFORMATION:

	PATENT NO	KIND DATE
	EP 484281	B1 19970109
'OFFENLEGUNGS' DATE:		19920506
APPLICATION INFO.:	EP 1991-310341	19911030
PRIORITY APPLN. INFO.:	GB 1990-13359	19901102
	GB 1990-23972	19901105
	GB 1990-23970	19901105
	GB 1990-23971	19901105
	GB 1991-16836	19910805
REFERENCE PAT. INFO.:	EP 373260 A	GB 2027244 A
	US 4814323 A	

L131 ANSWER 34 OF 38 EUROPATEFULL COPYRIGHT 2002 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 444897 EUROPATEFULL EW 199136 FS OS STA B
TITLE: Novel immunosuppressive **cyclosporin** analogs with modified amino acids at position-3.
Neue immunosuppressive Cyclosporinanaloge mit modifizierten Aminosaeuren in Position 3.
Nouvelles analogues immunosuppressives de la cyclosporine avec des acides aminees modifiees dans la position 3.
INVENTOR(S): Patchett, Arthur A., 1090 Minnsink Way, Westfield, NJ 07090, US;
Taub, David, 54 Wistar Avenue, Metuchen, NJ 08840, US;
Goegelman, Robert T., 437 Academy Terrace, Linden, NJ 07036, US
PATENT ASSIGNEE(S): MERCK & CO. INC., 126, East Lincoln Avenue P.O. Box 2000, Rahway New Jersey 07065-0900, US
PATENT ASSIGNEE NO: 200479
AGENT: Thompson, John Dr. et al, Merck & Co., Inc. European Patent Department Terlings Park Eastwick Road, Harlow, Essex CM20 2QR, GB
AGENT NUMBER: 62771
OTHER SOURCE: ESP1991064 EP 0444897 A1 910904
SOURCE: Wila-EFZ-1991-H36-T1
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: E CH; F DE; R FR; F GB; F IT; R LI; R NL
PATENT INFO.PUB.TYPE: EPA1 EUROPAEISCHE PATENTANMELDUNG
PATENT INFORMATION:

	PATENT NO	KIND DATE
	EP 444897	A1 19910904
'OFFENLEGUNGS' DATE:		19910904
APPLICATION INFO.:	EP 1991-301531	19910927
PRIORITY APPLN. INFO.:	US 1990-485920	19900927

L191 ANSWER 35 OF 38 EUROPATEFULL COPYRIGHT 2002 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 307077 EUROPATEFULL EW 198911 FS OS STA B
TITLE: Tetrahydrocarbazoles for the improvement of **cyclosporin** therapy.

Tetrahydrocarbazole zur Verbesserung der
Cyclosporintherapie.
Tetrahydrocarbazoles pour une therapie avec de la
cyclosporine.

INVENTOR(S): Ford-Hutchinson, Anthony W., 59 Hyde Park, Beaconsfield,
QUE H9W 5L7, CA

PATENT ASSIGNEE(S): MERCK PROSST CANADA INC., 16711 Trans-Canada Highway,
Kirkland Quebec, CA

PATENT ASSIGNEE NO: 123670

AGENT: Hesketh, Alan, Dr. et al, European Patent Department
Merck & Co., Inc. Terlings Park Eastwick Road, Harlow
Essex, CM20 2QR, GB

AGENT NUMBER: 31763

OTHER SOURCE: ESP1989011 EP 0307077 A1 890315

SOURCE: Wila-EP2-1989-H11-T1

DOCUMENT TYPE: Patent

LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch

DESIGNATED STATES: F CH; F DE; F FR; F GB; F IT; F LI; F NL

PATENT INFO.PUB.TYPE: EPAL EUROPÄISCHE PATENTANMELDUNG

PATENT INFORMATION:

	PATENT NO	KIND DATE
	EP 307077	A1 19890315
'OFFENLEGUNGS' DATE:		19890315
APPLICATION INFO.:	EP 1988-306563	19880713
PRIORITY APPLN. INFO.:	US 1987-76093	19870721

L181 ANSWER 36 OF 38 EUROPATFULL COPYRIGHT 2002 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 296123 EUROPATFULL EW 198851 FS OS STA B

TITLE: Cyclic peptolides.
Zyklische Peptolide.
Peptolides cycliques.

INVENTOR(S): Dreyfuss, Michael Morris, Paradieshofstrasse 82, CH-4054
Basle, CH;
Schreier, Max H., Oberwilerstrasse 50, CH-4054 Basle,
CH;
Tscherter, Hans, Baselmattweg 191/31, CH-4123 Allschwil,
CH;
Wenger, Roland, Grenzacherweg 45, CH-4125 Riehen, CH

PATENT ASSIGNEE(S): SANDOZ AG, Lichtstrasse 35, CH-4002 Basel, CH, in BE,
CH, ES, FR, GB, GR, IT, LI, LU, NL, SE;
SANDOZ-PATENT-GMBH, Humboldtstrasse 3, D-7850 Loerrach,
DE, in DE;
SANDOZ-ERFINDUNGEN Verwaltungsgesellschaft m.b.H.,
Brunner Strasse 59, A-1235 Wien, AT, in AT

PATENT ASSIGNEE NO: 201941; 498060; 498070

OTHER SOURCE: ESP1988048 EP 0296123 A2 881221

SOURCE: Wila-EP2-1988-H51-T1

DOCUMENT TYPE: Patent

LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch

DESIGNATED STATES: F AT; F BE; F CH; F DE; F ES; F FR; F GB; F GR; F IT; F
LI; F LU; F NL; F SE

PATENT INFO.PUB.TYPE: EPAL EUROPÄISCHE PATENTANMELDUNG

PATENT INFORMATION:

	PATENT NO	KIND DATE
	EP 296123	A2 19881221
'OFFENLEGUNGS' DATE:		19881221
APPLICATION INFO.:	EP 1988-310408	19880615
PRIORITY APPLN. INFO.:	CH 1987-2317	19870619
	CH 1987-2517	19870702

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 196123 EUROPATFULL EW 199435 FS PS STA B
 TITLE: Cyclic peptolides.
 Zyklische Peptolide.
 Peptolides cycliques.
 INVENTOR(S): Dreyfuss, Michael Morris, Paradieshofstrasse 82, CH-4054 Basle, CH;
 Schreier, Max H., Oberwilerstrasse 50, CH-4054 Basle, CH;
 Tschertter, Hans, Baselmattweg 191/31, CH-4123 Allschwil, CH;
 Wenger, Roland, Grenzacherweg 45, CH-4125 Fiehen, CH;
 Haslberger, Alexander, Dr., Prehausergasse 41, A-1130 Wien, AT
 PATENT ASSIGNEE(S): SANDOZ AG, Lichtstrasse 35, CH-4002 Basel, CH, in BE, CH, ES, FR, GB, GR, IT, LI, LU, NL, SE;
 SANDOZ-PATENT-GMBH, Humboldtstrasse 3, D-79539 Loerrach, DE, in DE;
 SANDOZ-ERFINDUNGEN Verwaltungsgesellschaft m.b.H., Brunner Strasse 59, A-1230 Wien, AT, in AT
 PATENT ASSIGNEE NO: 201941; 498060; 498070
 OTHER SOURCE: EPB1994061 EP 0296123 B1 940831
 SOURCE: Wila EPS-1994-H35 T1
 DOCUMENT TYPE: Patent
 LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
 DESIGNATED STATES: R AT; R BE; R CH; R DE; R ES; R FR; R GB; R GR; R IT; R LI; R LU; R NL; R SE
 PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCRIPT
 PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 096123	B1	19940831
		19881221
APPLICATION INFO.:	EP 1988-210408	19880615
PRIORITY APPLN. INFO.:	CH 1987-2317	19870619
	CH 1987-2517	19870702
REFERENCE PAT. INFO.:	GB 2061946	A

L181 ANSWER 37 OF 38 EUROPATFULL COPYRIGHT 2002 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 296122 EUROPATFULL EW 198851 FS OS STA B
 TITLE: Cyclosporins and their use as pharmaceuticals.
 Cyclosporine und deren Benutzung als Arzneimittel.
 Cyclosporines et leur emploi comme medicaments.
 INVENTOR(S): Bollinger, Pietro, Gustackerstrasse 56, CH-4103 Bottmingen, CH;
 Koelsterli, Johann Jakob, Brunnegasse, CH-4463 Buus, CH;
 Borel, Jean-Francois, Dornachweg 4, CH-4144 Arlesheim, CH;
 Krieger, Manfred, Hauptstrasse 91, CH-4422 Arisdorf, CH;
 Payne, Trevor Glyn, Dalmazirain 26, CH-3005 Bern, CH;
 Traber, Rene P., Wilhelm-His-Strasse 11, CH-4056 Basel, CH;
 Wenger, Roland, Grenzacherweg 45, CH-4125 Fiehen, CH
 PATENT ASSIGNEE(S): SANDOZ AG, Lichtstrasse 35, CH-4002 Basel, CH, in BE, CH, ES, FR, GB, GR, IT, LI, LU, NL, SE;
 SANDOZ-PATENT-GMBH, Humboldtstrasse 3, D-7850 Loerrach, DE, in DE;
 SANDOZ-ERFINDUNGEN Verwaltungsgesellschaft m.b.H., Brunner Strasse 59, A-1235 Wien, AT, in AT
 PATENT ASSIGNEE NO: 201941; 498060; 498070
 OTHER SOURCE: ESP1988048 EP 0296122 A2 881221

SOURCE: Wila-EP3-1988-H51-T1
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: F AT; R BE; R CH; R DE; R ES; R FR; R GB; R GR; R IT; R LI; R LU; R NL; R SE
PATENT INFO.PUB.TYPE: EP02 EUROPÄISCHE PATENTANMELDUNG
PATENT INFORMATION:

PATENT NO	KIND DATE
EP 296122	A2 19881221
	19881221
EP 1988-810403	19880614
GB 1987-14100	19870617
GB 1987-14090	19870617
GB 1987-14093	19870617
GB 1987-14098	19870617
GB 1987-14115	19870617
GB 1987-14118	19870617
GB 1987-14119	19870617
GB 1987-14125	19870617

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 296122 EUROPATEFULL EW 199339 FS PS STA B
TITLE: **Cyclosporins** and their use as pharmaceuticals.
Cyclosporine und deren Benutzung als Arzneimittel.
Cycloporines et leur emploi comme medicaments.
INVENTOR(S): Bollinger, Pietro, Gustackerstrasse 56, CH-4103
Bottmingen, CH;
Boelsterli, Johann Jakob, Brunnigasse, CH-4463 Buus, CH;
Borel, Jean-Francois, Dornachweg 4, CH-4144 Arlesheim,
CH;
Krieger, Manfred, Hauptstrasse 91, CH-4422 Arisdorf, CH;
Payne, Trevor Glyn, Dalmazirain 26, CH-3005 Bern, CH;
Traber, Rene P., Wilhelm His-Strasse 11, CH-4056 Basel,
CH;
Wenger, Roland, Grenzacherweg 45, CH-4125 Riehen, CH
PATENT ASSIGNEE(S): SANDOZ AG, Lichtstrasse 35, CH-4002 Basel, CH, in BE,
CH, ES, FR, GB, GR, IT, LI, LU, NL, SE;
SANDOZ-PATENT-GMBH, Humboldtstrasse 3, D-79539 Loerrach,
DE, in DE;
SANDOZ-ERFINDUNGEN Verwaltungsgesellschaft m.b.H.,
Brunner Strasse 59, A-1230 Wien, AT, in AT
PATENT ASSIGNEE NO: 201941; 498060; 498070
OTHER SOURCE: EPB1993051 EP 0296122 B1 930929
SOURCE: Wila-EPS-1993-H39-T1
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: F AT; R BE; R CH; R DE; R ES; R FR; R GB; R GR; R IT; R LI; R LU; R NL; R SE
PATENT INFO.PUB.TYPE: EPB1 EUROPÄISCHE PATENT-SCHRIFT
PATENT INFORMATION:

PATENT NO	KIND DATE
EP 296122	B1 19930929
	19881221
EP 1988-810403	19880614
GB 1987-14100	19870617
GB 1987-14090	19870617
GB 1987-14093	19870617
GB 1987-14098	19870617
GB 1987-14115	19870617
GB 1987-14118	19870617
GB 1987-14119	19870617
GB 1987-14125	19870617

'OFFENLEGUNGS' DATE: 19881221
APPLICATION INFO.: EP 1988-810403 19880614
PRIORITY APPLN. INFO.: GB 1987-14100 19870617
GB 1987-14090 19870617
GB 1987-14093 19870617
GB 1987-14098 19870617
GB 1987-14115 19870617
GB 1987-14118 19870617
GB 1987-14119 19870617
GB 1987-14125 19870617

REFERENCE PAT. INFO.: EP 194972 A GB 2155936 A

L181 ANSWER 38 OF 38 EUROPATFULL COPYRIGHT 2002 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 194972 EUROPATFULL EW 199231 FS PS STA B

TITLE: Novel **cyclosporins**.

Cyclosporine.

Cyclosporines.

INVENTOR(S): Seebach, Dieter, Orellistrasse 3, CH-8044 Zurich, CH

PATENT ASSIGNEE(S): SANDOZ AG, Lichtstrasse 35, CH-4002 Basel, CH, in BE,

CH, FR, GB, IT, LI, LU, NL, SE;

SANDOZ-PATENT-GMBH, Humboldtstrasse 3, W-7850 Loerrach,

DE, in DE;

SANDOZ-ERFINDUNGEN Verwaltungsgesellschaft m.b.H.,

Brunner Strasse 59, A-1235 Wien, AT, in AT

PATENT ASSIGNEE NO: 201941; 498060; 498070

OTHER SOURCE: EPB1992038 EP 0194972 B1 920729

SOURCE: Wila-EPS-1992-H31-T1

DOCUMENT TYPE: Patent

LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch

DESIGNATED STATES: R AT; R BE; R CH; R DE; R FR; R GB; R IT; R LI; R LU; R

NL; R SE

PATENT INFO.PUB.TYPE: EPB1 EUROPÄISCHE PATENTSCHRIFT

PATENT INFORMATION:

PATENT NO

KIND DATE

EP 194972

B1 19920729

'OFFENLEGUNGS' DATE:

19850917

APPLICATION INFO.:

EP 1985-810112

19850306

PRIORITY APPLN. INFO.:

GB 1985-5230

19850311

GB 1985-11029

19850501

GB 1986-2370

19860131

REFERENCE PAT. INFO.:

EP 56782 A

=>

L361 ANSWER 1 OF 5 USPATFULL

ACCESSION NUMBER: 2000:224588 USPATEFULL
TITLE: Methods of using inhibitors of cyclophilin rotamase activity to affect neurological activity
INVENTOR(S): Steiner, Joseph P., Finksburg, MD, United States
Hamilton, Gregory S., Catonsville, MD, United States
Snyder, Solomon H., Baltimore, MD, United States
PATENT ASSIGNEE(S): Guilford Pharmaceuticals Inc., Baltimore, MD, United States (U.S. corporation)
Johns Hopkins University School of Medicine, Baltimore, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6444643	B1	20020903
APPLICATION INFO.:	US 1994-321762		19990528 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-560685, filed on 20 Nov 1995, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Kuntz, Gary L.		
ASSISTANT EXAMINER:	Gucker, Stephen		
LEGAL REPRESENTATIVE:	Howrey Simon Arnold & White, LLP		
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)		
LINE COUNT:	923		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to the method of using neurotrophic cyclophilin inhibitor compounds having an affinity for cyclophilin-type immunophilins as inhibitors of the enzyme activity associated with immunophilin proteins, and particularly inhibitors of peptidyl-prolyl isomerase or rotamase enzyme activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L361 ANSWER 2 OF 5 USPATFULL

ACCESSION NUMBER: 2001:102610 USPATEFULL
TITLE: **Cyclosporin** fermentation process
INVENTOR(S): Ko, Soo Young, London, United Kingdom
Kobel, Hans, Basel, Switzerland
Besemer-Rosenwirth, Brigitte, Modling, Austria
Seebach, Dieter, Zurich, Switzerland
Traber, Rene P., Basel, Switzerland
Wenger, Roland, Fiehen, Switzerland
Bollinger, Pietro, Bottmingen, Switzerland
PATENT ASSIGNEE(S): Novartis AG, Basel, Switzerland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6255100	B1	20010703
APPLICATION INFO.:	US 1999-392282		19990909 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-84709, filed on 26 May 1998, now patented, Pat. No. US 5981479 Division of Ser. No. US 1995-427312, filed on 24 Apr 1995, now patented, Pat. No. US 5767069 Continuation of Ser. No. US 1994-232795, filed on 25 Apr 1994, now abandoned Continuation of Ser. No. US 1993-57067, filed on 3 May 1993, now abandoned Continuation of Ser. No. US 1991-785959, filed on 31 Oct 1991, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1990-23859	19901102
	GB 1990-23970	19901105

GB 1990-13971 19901105
GB 1990-13972 19901105
GB 1991-16836 19910805

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Wessendorf, T. D.
LEGAL REPRESENTATIVE: Lopez, Gabriel
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 309

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB It has been found that nonimmunosuppressive, cyclophilin-binding **cyclosporins** are useful in the treatment and prevention of AIDS and AIDS-related disorders. Such **cyclosporins** include novel cyclosporin derivatives modified at the 4- and/or 5-positions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L361 ANSWER 3 OF 5 USPATFULL

ACCESSION NUMBER: 1999:141886 USPATFULL

TITLE: **Cyclosporins**

INVENTOR(S): Ko, Soo Young, London, United Kingdom
Kobel, Hans, Basel, Switzerland
Besemer-Rosenwirth, Brigitte, Modling, Austria
Seebach, Dieter, Zurich, Switzerland
Traber, Rene P., Basel, Switzerland
Wenger, Roland, Riehen, Switzerland
Bollinger, Pietro, Bottmingen, Switzerland
PATENT ASSIGNEE(S): Novartis AG, Basel, Switzerland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5981479		19991109
APPLICATION INFO.:	US 1998-84709		19980526 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-427312, filed on 24 Apr 1995, now patented, Pat. No. US 5767069		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1990-23859	19901105
	GB 1990-23970	19901105
	GB 1990-23971	19901105
	GB 1990-23972	19901105
	GB 1991-16836	19910805

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Tsang, Cecilia J.
LEGAL REPRESENTATIVE: Lopez, Gabriel, Furman, Diane E.
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 841

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB It has been found that nonimmunosuppressive, cyclophilin-binding **cyclosporins** are useful in the treatment and prevention of AIDS and AIDS-related disorders. Such **cyclosporins** include novel cyclosporin derivatives modified at the 4- and/or 5-positions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L361 ANSWER 4 OF 5 USPATFULL

ACCESSION NUMBER: 1998:68992 USPATFULL

TITLE: **Cyclosporins**

INVENTOR(S): Ko, Soo Young, London, Great Britain

Kobel, Hans, Basel, Switzerland
Besemer-Rosenwirth, Brigitte, Modling, Austria
Seebach, Dieter, Zurich, Switzerland
Traber, Rene P., Basel, Switzerland
Wenger, Roland, Riehen, Switzerland
Bollinger, Pietro, Bottmingen, Switzerland
Novartis AG, Basel, Switzerland (non-U.S. corporation)

PATENT ASSIGNEE(S):

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5767069		19980616
APPLICATION INFO.:	US 1995-427312		19950424 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-232795, filed on 25 Apr 1994, now abandoned which is a continuation of Ser. No. US 1993-57067, filed on 3 May 1993, now abandoned which is a continuation of Ser. No. US 1991-785959, filed on 31 Oct 1991, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1990-23859	19901102
	GB 1990-23970	19901105
	GB 1990-23971	19901105
	GB 1990-23972	19901105
	GB 1991-16836	19910805

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Achutamurthy, Pennathapura
ASSISTANT EXAMINER: Wessendorf, T. D.
LEGAL REPRESENTATIVE: Mathias, Marla J., McGovern, Thomas O.
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 779

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Nonimmunosuppressant **cyclosporin** derivatives having cyclophilin-binding activity, for example, the compound, [Meile].sup.4 -ciclosporin, are useful in inhibiting HIV-1 replication in treating AIDS and AIDS related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L361 ANSWER 5 OF 5 EUROPATFULL COPYRIGHT 2002 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 494281 EUROPATFULL EW 199219 FS OS STA B
TITLE: **Cyclosporins.**
Zyklosporine.
Cyclosporines.

INVENTOR(S): Ko, Soo Young, Flat 5, 42 Belsize Park Gardens, London NW3 4LY, GB;
Kobel, Hans, Weissensteinstrasse 1, CH-4059 Basle, CH;
Rosenwirth, Brigitte, C. Zwillinggasse 17, A-2340 Moedling, AT;
Seebach, Dieter, Orellistrasse 3, CH-8044 Zuerich, CH;
Traber, Rene P., Hirzbodenpark 20, CH-4052 Basle, CH;
Wenger, Roland, Grenzacherweg 45, CH-4125 Riehen, CH;
Bollinger, Pietro, Gustackerstrasse 56, CH-4103 Bottmingen, CH

PATENT ASSIGNEE(S): SANDOZ LTD., Lichtstrasse 35, CH-4002 Basel, CH, in BE, CH, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE;
SANDOZ-PATENT-GMBH, Humboldtstrasse 3, W-7850 Loerrach, DE, in DE;
SANDOZ ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H.,

Brunner Strasse 59, A-1235 Vienna, AT, in AT
 PATENT ASSIGNEE NO: 101940; 498060; 1297990
 OTHER SOURCE: ESP1992035 EP 0484281 A2 920506
 SOURCE: Wila-EP2-1992-H19-T1
 DOCUMENT TYPE: Patent
 LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
 DESIGNATED STATES: E AT; E BE; E CH; E DE; E DK; E ES; E FR; E GB; E GR; E
 IT; E LI; E LU; E NL; E SE
 PATENT INFO.PUB.TYPE: EPAL EUROPAEISCHE PATENTANMELDUNG
 PATENT INFORMATION:

	PATENT NO	KIND	DATE
'OFFENLEGUNGS' DATE:	EP 484281	A2	19910506
APPLICATION INFO.:			19920506
PRIORITY APPLN. INFO.:	EP 1991-810841		19911030
	GB 1990-23859		19901102
	GB 1990-23972		19901105
	GB 1990-23970		19901105
	GB 1990-23971		19901105
	GB 1991-16836		19910805

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 494281 EUROPAFULL EW 199705 FS PS
 TITLE:

Cyclosporins.
 Zyklosporine.
 Cyclosporines.

INVENTOR(S): Ko, Soo Young, Flat 5, 42 Belsize Park Gardens, London
 NW3 4LY, GB;
 Kobel, Hans, Weissensteinstrasse 1, CH-4059 Basle, CH;
 Rosenwirth, Brigitte, C. Zwillinggasse 17, A-2340
 Moedling, AT;
 Seebach, Dieter, Orellistrasse 3, CH-8044 Zuerich, CH;
 Traber, Rene P., Hirzbodenpark 20, CH-4052 Basle, CH;
 Wenger, Roland, Grenzacherweg 45, CH-4125 Riehen, CH;
 Bollinger, Pietro, Gustackerstrasse 56, CH-4103
 Rottmingen, CH

PATENT ASSIGNEE(S): SANDOZ LTD., Lichtstrasse 35, 4002 Basel, CH, in BE, CH,
 DK, ES, FR, GB, GR, IT, LI, LU, NL, SE;
 SANDOZ-PATENT-GMBH, Humboldtstrasse 3, 79539 Loerrach,
 DE, in DE;
 SANDOZ ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H.,
 Brunner Strasse 59, 1235 Wien, AT, in AT

PATENT ASSIGNEE NO: 201940; 498060; 1297990
 OTHER SOURCE: EPB1997009 EP 0484281 B1 970129
 SOURCE: Wila-EFS-1997-H05-T1
 DOCUMENT TYPE: Patent
 LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
 DESIGNATED STATES: E AT; E BE; E CH; E DE; E DK; E ES; E FR; E GB; E GR; E
 IT; E LI; E LU; E NL; E SE
 PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT
 PATENT INFORMATION:

	PATENT NO	KIND	DATE
'OFFENLEGUNGS' DATE:	EP 484281	B1	19970129
APPLICATION INFO.:			19920506
PRIORITY APPLN. INFO.:	EP 1991-810841		19911030
	GB 1990-23859		19901102
	GB 1990-23972		19901105
	GB 1990-23970		19901105
	GB 1990-23971		19901105
	GB 1991-16836		19910805
REFERENCE PAT. INFO.:	EP 373260 A		GB 2227244 A
	US 4814323 A		

L361 ANSWER 1 OF 5 USPATFULL

ACCESSION NUMBER: 2002:224588 USPATFULL
TITLE: Methods of using inhibitors of cyclophilin rotamase activity to affect neurological activity
INVENTOR(S): Steiner, Joseph P., Finksburg, MD, United States
Hamilton, Gregory S., Catonsville, MD, United States
Snyder, Solomon H., Baltimore, MD, United States
PATENT ASSIGNEE(S): Guilford Pharmaceuticals Inc., Baltimore, MD, United States (U.S. corporation)
Johns Hopkins University School of Medicine, Baltimore, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6444643	B1	20020903
APPLICATION INFO.:	US 1999-321762		19990528 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-560685, filed on 20 Nov 1995, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Kunz, Gary L.		
ASSISTANT EXAMINER:	Gucker, Stephen		
LEGAL REPRESENTATIVE:	Howrey Simon Arnold & White, LLP		
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)		
LINE COUNT:	923		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to the method of using neurotrophic cyclophilin inhibitor compounds having an affinity for cyclophilin-type immunophilins as inhibitors of the enzyme activity associated with immunophilin proteins, and particularly inhibitors of peptidyl-prolyl isomerase or rotamase enzyme activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 1261 1-5 ibib abs

L261 HAS NO ANSWERS

L1 QUE ABB=ON PLU=ON CYCLOSPORIN AND (SYNTHESIS OR SYNTHESIS)
L21 16 SEA FILE=IFIPAT ABB=ON PLU=ON L1 AND ALKYL
L201 0 SEA FILE=IFIPAT ABB=ON PLU=ON L21 AND (POSITION (W) 4 OR 4 (W) POSITION)
L261 0 SEA FILE=IFIPAT ABB=ON PLU=ON L201 AND PHARMACEUTICAL

=> d 361 1-5 ibib abs

5 ANSWERS ARE AVAILABLE. SPECIFIED ANSWER NUMBER EXCEEDS ANSWER SET SIZE
The answer numbers requested are not in the answer set.

ENTER ANSWER NUMBER OR RANGE (1):1361

ANSWER NUMBERS NOT CORRECTLY SPECIFIED

Enter an answer number, Example: 10
several answer numbers, Example: 3,7,10
a range of answer numbers, Example: 5-10
or a combination of these. Example: 3,7,9-10,15

ENTER ANSWER NUMBER OR RANGE (1):

<-----User Break----->

ENTER ANSWER NUMBER OR RANGE (1):1361 1-5 ibib bas

ANSWER NUMBERS NOT CORRECTLY SPECIFIED

Enter an answer number, Example: 10
several answer numbers, Example: 3,7,10
a range of answer numbers, Example: 5-10
or a combination of these. Example: 3,7,9-10,15

ENTER ANSWER NUMBER OR RANGE (1):

<-----User Break----->

ENTER ANSWER NUMBER OR RANGE (1): d l361 1-5 ibib bas

ANSWER NUMBERS NOT CORRECTLY SPECIFIED

Enter an answer number, Example: 10
several answer numbers, Example: 3,7,10
a range of answer numbers, Example: 5-10
or a combination of these. Example: 3,7,9-10,15

ENTER ANSWER NUMBER OR RANGE (1):all

ANSWER NUMBERS NOT CORRECTLY SPECIFIED

Enter an answer number, Example: 10
several answer numbers, Example: 3,7,10
a range of answer numbers, Example: 5-10
or a combination of these. Example: 3,7,9-10,15

ENTER ANSWER NUMBER OR RANGE (1):d l361 all

ANSWER NUMBERS NOT CORRECTLY SPECIFIED

Enter an answer number, Example: 10
several answer numbers, Example: 3,7,10
a range of answer numbers, Example: 5-10
or a combination of these. Example: 3,7,9-10,15

ENTER ANSWER NUMBER OR RANGE (1):1-5

L361 ANSWER 1 OF 5 USPATFULL

ACCESSION NUMBER: 2002:224588 USPATFULL

TITLE: Methods of using inhibitors of cyclophilin rotamase activity to affect neurological activity

INVENTOR(S): Steiner, Joseph P., Finksburg, MD, United States
Hamilton, Gregory S., Catonsville, MD, United States
Snyder, Solomon H., Baltimore, MD, United States

PATENT ASSIGNEE(S): Guilford Pharmaceuticals Inc., Baltimore, MD, United States (U.S. corporation)
Johns Hopkins University School of Medicine, Baltimore, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6444643	B1	20020903
APPLICATION INFO.:	US 1999-321762		19990528 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-560685, filed on 20 Nov 1995, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Kunz, Gary L.		
ASSISTANT EXAMINER:	Gucker, Stephen		
LEGAL REPRESENTATIVE:	Howrey Simon Arnold & White, LLP		
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)		
LINE COUNT:	923		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to the method of using neurotrophic cyclophilin inhibitor compounds having an affinity for cyclophilin-type immunophilins as inhibitors of the enzyme activity associated with immunophilin proteins, and particularly inhibitors of peptidyl-prolyl isomerase or rotamase enzyme activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L361 ANSWER 2 OF 5 USPATFULL

ACCESSION NUMBER: 2001:102610 USPATFULL

TITLE: **Cyclosporin** fermentation process

INVENTOR(S): Ko, Soo Young, London, United Kingdom
Kobel, Hans, Basel, Switzerland
Besemer-Rosenwirth, Brigitte, Modling, Austria
Seebach, Dieter, Zurich, Switzerland
Traber, ReneP., Basel, Switzerland

Wenger, Roland, Riehen, Switzerland
Bollinger, Pietro, Bottmingen, Switzerland
PATENT ASSIGNEE(S): Novartis AG, Basel, Switzerland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6255100	B1	20010703
APPLICATION INFO.:	US 1999-392282		19990909 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-84709, filed on 26 May 1998, now patented, Pat. No. US 5981479 Division of Ser. No. US 1995-427312, filed on 24 Apr 1995, now patented, Pat. No. US 5767069 Continuation of Ser. No. US 1994-232795, filed on 25 Apr 1994, now abandoned Continuation of Ser. No. US 1993-57067, filed on 3 May 1993, now abandoned Continuation of Ser. No. US 1991-785959, filed on 31 Oct 1991, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1990-23859	19901102
	GB 1990-23970	19901105
	GB 1990-23971	19901105
	GB 1990-23972	19901105
	GB 1991-16836	19910805
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Wessendorf, T. D.	
LEGAL REPRESENTATIVE:	Lopez, Gabriel	
NUMBER OF CLAIMS:	3	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 3 Drawing Page(s)	
LINE COUNT:	809	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB It has been found that nonimmunosuppressive, cyclophilin-binding **cyclosporins** are useful in the treatment and prevention of AIDS and AIDS-related disorders. Such **cyclosporins** include novel Ciclosporin derivatives modified at the 4- and/or 5-positions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L361 ANSWER 3 OF 5 USPATFULL

ACCESSION NUMBER: 1999:141886 USPATFULL
TITLE: **Cyclosporins**
INVENTOR(S): Ko, Soo Young, London, United Kingdom
Kobel, Hans, Basel, Switzerland
Besemer-Rosenwirth, Brigitte, Modling, Austria
Seebach, Dieter, Zurich, Switzerland
Traber, Rene P., Basel, Switzerland
Wenger, Roland, Riehen, Switzerland
Bollinger, Pietro, Bottmingen, Switzerland
PATENT ASSIGNEE(S): Novartis AG, Basel, Switzerland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5981479		19991109
APPLICATION INFO.:	US 1998-84709		19980526 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-427312, filed on 24 Apr 1995, now patented, Pat. No. US 5767069		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1990-23859	19901102
	GB 1990-23970	19901105
	GB 1990-23971	19901105
	GB 1990-23972	19901105
	GB 1991-16836	19910805

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Tsang, Cecilia J.
LEGAL REPRESENTATIVE: Lopez, Gabriel, Furman, Diane E.
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 841

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB It has been found that nonimmunosuppressive, cyclophilin-binding **cyclosporins** are useful in the treatment and prevention of AIDS and AIDS-related disorders. Such **cyclosporins** include novel Ciclosporin derivatives modified at the 4- and/or 5-positions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L361 ANSWER 4 OF 5 USPATFULL

ACCESSION NUMBER: 1998:68992 USPATFULL
TITLE: **Cyclosporins**
INVENTOR(S): Ko, Soo Young, London, Great Britain
Kobel, Hans, Basel, Switzerland
Besemer-Rosenwirth, Brigitte, Modling, Austria
Seebach, Dieter, Zurich, Switzerland
Traber, Rene P., Basel, Switzerland
Wenger, Roland, Riehen, Switzerland
Bollinger, Pietro, Bottmingen, Switzerland
PATENT ASSIGNEE(S): Novartis AG, Basel, Switzerland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5767069		19980616
APPLICATION INFO.:	US 1995-427312		19950424 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-232795, filed on 25 Apr 1994, now abandoned which is a continuation of Ser. No. US 1993-57067, filed on 3 May 1993, now abandoned which is a continuation of Ser. No. US 1991-785959, filed on 31 Oct 1991, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1990-23859	19901102
	GB 1990-23970	19901105
	GB 1990-23971	19901105
	GB 1990-23972	19901105
	GB 1991-16836	19910805

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Achutamurthy, Ponnathapura
ASSISTANT EXAMINER: Wessendorf, T. D.
LEGAL REPRESENTATIVE: Mathias, Marla J., McGovern, Thomas O.
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 779

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Nonimmunosuppressant **cyclosporin** derivatives having cyclophilin-binding activity, for example, the compound, [MeIle].sup.4 -ciclosporin, are useful in inhibiting HIV-1 replication in treating AIDS and AIDS related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L361 ANSWER 5 OF 5 EUROPATFULL COPYRIGHT 2002 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 484281 EUROPATFULL EW 199219 FS OS STA B
 TITLE: **Cyclosporins.**
 Zyklosporine.
 Cyclosporines.
 INVENTOR(S): Ko, Soo Young, Flat 5, 42 Belsize Park Gardens, London
 NW3 4LY, GB;
 Kobel, Hans, Weissensteinstrasse 1, CH-4059 Basle, CH;
 Rosenwirth, Brigitte, C. Zwillinggasse 17, A-2340
 Moedling, AT;
 Seebach, Dieter, Orellistrasse 3, CH-8044 Zuerich, CH;
 Traber, Rene P., Hirzbodenpark 20, CH-4052 Basle, CH;
 Wenger, Roland, Grenzacherweg 45, CH-4125 Riehen, CH;
 Bollinger, Pietro, Gustackerstrasse 56, CH-4103
 Bottmingen, CH
 PATENT ASSIGNEE(S): SANDOZ LTD., Lichtstrasse 35, CH-4002 Basel, CH, in BE,
 CH, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE;
 SANDOZ-PATENT-GMBH, Humboldtstrasse 3, W-7850 Loerrach,
 DE, in DE;
 SANDOZ EPFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H.,
 Brunner Strasse 59, A-1235 Vienna, AT, in AT
 PATENT ASSIGNEE NO: 201940; 498060; 1297990
 OTHER SOURCE: ESP1992035 EP 0484281 A2 920506
 SOURCE: Wila-EPZ-1992-H19-T1
 DOCUMENT TYPE: Patent
 LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
 DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R
 IT; R LI; R LU; R NL; R SE
 PATENT INFO.PUB.TYPE: EPA2 EUROPAEISCHE PATENTANMELDUNG
 PATENT INFORMATION:

PATENT NO	KIND DATE
EP 484281	A2 19920506
	19920506
EP 1991-810841	19911030
GB 1990-23859	19901102
GB 1990-23972	19901105
GB 1990-23970	19901105
GB 1990-23971	19901105
GB 1991-16836	19910805

'OFFENLEGUNGS' DATE:

APPLICATION INFO.: EP 1991-810841

PRIORITY APPLN. INFO.: GB 1990-23859

GB 1990-23972

GB 1990-23970

GB 1990-23971

GB 1991-16836

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 484281 EUROPATFULL EW 199705 FS PS

TITLE: **Cyclosporins.**

Zyklosporine.

Cyclosporines.

INVENTOR(S): Ko, Soo Young, Flat 5, 42 Belsize Park Gardens, London

NW3 4LY, GB;

Kobel, Hans, Weissensteinstrasse 1, CH-4059 Basle, CH;

Rosenwirth, Brigitte, C. Zwillinggasse 17, A-2340

Moedling, AT;

Seebach, Dieter, Orellistrasse 3, CH-8044 Zuerich, CH;

Traber, Rene P., Hirzbodenpark 20, CH-4052 Basle, CH;

Wenger, Roland, Grenzacherweg 45, CH-4125 Riehen, CH;

Bollinger, Pietro, Gustackerstrasse 56, CH-4103

Bottmingen, CH

PATENT ASSIGNEE(S): SANDOZ LTD., Lichtstrasse 35, 4002 Basel, CH, in BE, CH,

DK, ES, FR, GB, GR, IT, LI, LU, NL, SE;

SANDOZ-PATENT-GMBH, Humboldtstrasse 3, 79539 Loerrach,

DE, in DE;

SANDOZ ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H.,

Brunner Strasse 59, 1235 Wien, AT, in AT

PATENT ASSIGNEE NO: 201940; 498060; 1297990

OTHER SOURCE: EPB1997009 EP 0484281 B1 970129

SOURCE: Wila-EPS-1997-H05-T1

DOCUMENT TYPE: Patent

LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R
IT; R LI; R LU; R NL; R SE
PATENT INFO.PUB.TYPE: EPB1 EUROPÄISCHE PATENTSCHRIFT
PATENT INFORMATION:

	PATENT NO	KIND DATE
	-----	-----
	EP 484281	B1 19970129
'OFFENLEGUNGS' DATE:		19920506
APPLICATION INFO.:	EP 1991-810841	19911030
PRIORITY APPLN. INFO.:	GB 1990-23859	19901102
	GB 1990-23972	19901105
	GB 1990-23970	19901105
	GB 1990-23971	19901105
	GB 1991-16836	19910805
REFERENCE PAT. INFO.:	EP 373260 A	GB 2227244 A
	US 4814323 A	

=>